University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Student Research Projects, Dissertations, and
Theses - Chemistry Department

Chemistry, Department of

12-2020

The Application and Development of Metabolomics
Methodologies for the Profiling of Food and Cellular Toxicity
Jade Woods
University of Nebraska-Lincoln, jade.woods@huskers.unl.edu

Follow this and additional works at: https://digitalcommons.unl.edu/chemistrydiss
Part of the Analytical Chemistry Commons

Woods, Jade, "The Application and Development of Metabolomics Methodologies for the Profiling of
Food and Cellular Toxicity" (2020). Student Research Projects, Dissertations, and Theses - Chemistry
Department. 104.
https://digitalcommons.unl.edu/chemistrydiss/104

This Article is brought to you for free and open access by the Chemistry, Department of at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Student Research
Projects, Dissertations, and Theses - Chemistry Department by an authorized administrator of
DigitalCommons@University of Nebraska - Lincoln.

THE APPLICATION AND DEVELOPMENT OF METABOLOMICS
METHODOLOGIES FOR THE PROFILING OF FOOD AND CELLULAR TOXICITY
by

Jade Woods

A THESIS

Presented to the Faculty of
The Graduate College at the University of Nebraska
In Partial Fulfillment of Requirements
For the Degree of Master of Science

Major: Chemistry
Under the Supervision of Professor Robert Powers
Lincoln, Nebraska
December, 2020

THE APPLICATION AND DEVELOPMENT OF METABOLOMICS
METHODOLOGIES FOR THE PROFILING OF FOOD AND CELLULAR TOXICITY

Jade Woods, M.S.
University of Nebraska, 2019
Advisor: Robert Powers
Metabolomics is a rapidly growing field of study. Its growth reflects advancements in
technology and an improved understanding of the impact of the environment on
metabolism. As a result, metabolomics is now commonly employed to investigate and
characterize human and plant metabolism. The first chapter of this thesis provides an
introduction to metabolomics and an overview of the protocols for sample preparation, data
collection and statistical analysis. The second thesis chapter describes in explicit detail the
step-by-step process of extracting and analyzing metabolites collected from mammalian
cells, specifically brain tissue with a focus on Parkinson’s disease. The chapter highlights
important factors to consider including experiment design, sample collection, and data
processing. Chapters 3 and 4 include the application of metabolomics to evaluate how the
metabolome responds to the environment. Chapter 3 focuses on the neuronal response to
the xenobiotic arsenic. It demonstrates how astrocytes increase glutathione production
through an up regulation of the citric acid cycle and glycolytic processes. Arsenic was also
observed to decreases related metabolites including citrate and lactate. These metabolites
are important intermediates to ATP production and illustrate the interconnection of
metabolomic processes. Chapter 4 shows how metabolite profiles can be used to evaluate
the impact of environmental conditions on wines. Metabolite profiles of Pinot Noir derived
from the same scion clone (Pinot noir 667) and grown in different regions along the Pacific

coast were compared. NMR and a differential sensing array were used to profile the
chemical composition of the samples. We observed how environmental conditions resulted
in different metabolite profiles in the various wine samples. This thesis aims to highlight
the application of metabolomic to various biological studies in order to evaluate the impact
of external stimuli.
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Chapter 1
1. Introduction
1.1 The Omics Field
The ‘omics’ field refers to a data driven approach to study entire biological systems by observing
the totality of the system rather than individual aspects of interest. Omics utilizes large quantities
of biological data made available from the development of high throughput technologies, which
includes the ability to quantify total levels of DNA, RNA, and proteins in a given system. By
quantifying the complete set of biomolecules, a global overview of the molecular processes present
in a system can be ascertained, and, accordingly, allows us to investigate and understand the
organism in its entirety. Conversely, a traditional reductionist approach is likely to miss important
relationships when only a single part is analyzed in isolation. Rather than studying individual genes
or proteins, the 'omics' approach takes a holistic view of a biological system to identify significant
variations in structure, function and/or biological activity.
The earliest ‘omics’ studies took advantage of large amounts of data from DNA sequencing
technology. For example, Sanger sequencing, allowed for the sequencing of entire organisms [1].
In this regard, genomics studies the entire genome rather than focusing on a specific set of genes
of interest. The usefulness and popularity of genomics is directly correlated with the rapid analysis
of genetic material from multiple organisms. Genomics allowed for the identification of novel
genes associated with diseases and disorders, and streamlined the investigation of the cellular and
functional role of specific genes [2]. Similarly, sequencing and microarrays allowed for the rapid
quantification of RNA. Transcriptomics measures the total cellular levels of RNA to study gene
expression and its role in disease [3]. Likewise, total cellular levels of proteins or the proteome is

2

identified and quantified with mass spectrometry (MS) or, occasionally, through assays [4].
Proteomics allows for a complete view on how proteins interact with drugs and the study of the
role of proteins in disease mechanisms [5].

1.2 The Metabolome and Metabolomics
The strength of ‘omics’ studies is the ability to evaluate the overall activity of a cell or organism
as a result of a disease state, environmental stressor, or genetic mutation. Transcriptomics
identifies changes in the transcription of genes. Proteomics analyzes changes in which RNA
sequences are translated into proteins. Figure 1.1 shows the central dogma of biology, which
illustrates how information flows from DNA to RNA to proteins. Metabolomics is the next logical
step in the ‘omics’ cascade. Metabolomics is an analytical science that focuses on the study of
metabolism. The discipline utilizes multiple analytical techniques and methods to quantify and
identify metabolites. Metabolites are the small molecular-weight (< 1,000 Da) compounds found
within a biofluid (e.g., serum, urine, etc.), cell, tissue, organ, or organism. Metabolites are
intermediates and products of numerous cellular processes, which includes energy production,
molecular and biomolecule synthesis, and signaling. Initially, metabolomics quantified
metabolites as an extension of functional genomics. Measured metabolite concentrations provides
a snapshot of the active metabolic processes which are then leveraged to identify the specific
metabolic pathways affected by disease, environmental stressors, or gene deletion [6]. The
observed metabolic dysfunction illustrates the downstream effects of a change in gene expression,
RNA translation, or protein activity. A gene deletion or mutation may result in protein inactivation.
Similarly, a disruption or a malfunction in transcription and/or translation may result in a decrease
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in protein concentrations [7]. Of course, these processes may also result in an increase in protein
activity or concentrations. Cellular processes are also regulated by various enzymes and proteins.
Thus, quantifying disruptions in metabolite levels may serve as a proxy of genetic variation as well
as a cellular response to external stressors [8]. External stressors, including toxins and bacteria,
may damage DNA or alter protein and/or enzyme function. The application of metabolomics
attempts to understand the biological response to various stressors. Metabolomics has increased
exponentially over the last decade, and is now routinely applied to a wide variety of scientific
concerns, including, food, nutrition, climate and environmental issues, human and livestock
diseases, personalized medicine, drug development, and disease diagnosis [9].

1.3 Application of Metabolomics
1.3.1 Metabolomics as a Tool to Studying Disease
Metabolomic dysfunction has been associated with human diseases for hundreds of years [10].
For example, diabetes mellitus is marked by the dysfunction in the production or functionality of
the hormone insulin [11]. Insulin plays multiple roles in carbohydrate metabolism including
defusing glucose into muscle and fat, and increasing the amount of glucose in the bloodstream.
Thus, insulin dysfunction may also result in hyperglycemia. Diabetes mellitus shares similar
symptoms with diabetes insipidus, which is marked by a dysfunction of the antidiuretic hormone
or receptor [12]. Biomarkers, in combination with clinical symptoms, are useful tools for disease
diagnosis and monitoring disease progression [13]. For example, biomarkers can be useful for
predicting the onset of neurodegenerative diseases such as Alzheimer’s disease [14]. Biomarkers
have been observed in blood, serum, and cerebral spinal fluid [15-17]. Metabolomics allows for
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the efficient discovery of novel biomarkers as well as linking diseases with metabolic
dysfunction(s). In addition to biomarkers, metabolomics may also provide insights into the
mechanism of a disease. Disease-associated metabolites or metabolic pathways may be used to
identify new therapeutic targets for drug development or to provide insights into drug resistance.
In fact, the more we understand about the underpinning processes of human diseases, the greater
the appreciation we obtain regarding the importance of metabolism in disease.

Figure 1.1: The central dogma of biochemistry illustrates the cascade of how information flows
down from DNA to proteins. DNA is transcribed into RNA, which codes for proteins. External
stressors, as well as inherited genetic variation result in downstream modification. Metabolomics,
therefore, can capture dysfunction through altered metabolite levels.
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Cancer is a disease that effected roughly 12 million Americans in 2008 with numbers expected to
grow [18]. Cancer is characterized by metabolic dysfunction, which is used to differentiate cancer
cells from healthy cells. For example, the “Warburg Effect” is a hallmark of cancer cells, which
exhibit higher levels of glycolysis and a higher consummation of glucose [19]. Notably, a more
efficient ATP production occurs through mitochondrial respiration and the citric acid (TCA) cycle
then glycolysis [20]. One potential explanation is the upregulation of hexokinase II in cancer cells,
which has been shown to be important for fixing glucose into glycolysis compared to oxidative
phosphorylation [21].
Diseases of the central nervous system (CNS) are also being investigated by leveraging complex
metabolomic processes in the brain. In this regard, metabolomics may provide an overview of
brain function or activity by monitoring various cellular processes. Neurodegenerative diseases,
which include Parkinson's Disease (PD), Alzheimer’s, and Huntington's Disease, are characterized
by the progressive death of neurons and the loss of neuronal activity. For example, PD is the result
of the death of dopaminergic neurons in the substantia nigra. The symptoms are progressive, start
small, and build over time. The major symptoms of PD are motor disorders including stiffness and
rigidity, which often start on one side of the body and then spreading throughout. There are also
multiple non-motor symptoms that include depression, sleep behavior disorders, and nausea [22].
PD is difficult to diagnose and treat since symptoms appear during the mid- to late-stages of disease
progression [23]. In 2010, roughly 630,000 individuals in America were diagnosed with PD with
an estimated yearly medical cost of 14.4 billion dollars [24].
The complex nature of the brain and the limited access to tissue samples complicates the diagnosis
of PD. Clinical tests that include neurological scans and a physician’s assessment of a response to
treatment are typical methods used to diagnose PD [25]. An early diagnosis of PD and the
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immediate initiation of treatment may result in reduced symptoms for patients. Early drugintervention has been suggested to slow down disease progression [26]. However, PD diagnosis is
difficult, requires the identification of specific symptoms, and often requires multiple physician
visits. Understanding how PD alters metabolism may be beneficial to the early diagnosis and for
monitoring disease progression through the use of biomarkers.
The pathogenesis of PD is not fully understood. However, a few risk factors have been linked to
the development of PD, which include age, genetics, and exposure to environmental toxins [27].
For example, exposure to copper or lead have been shown to be a high-risk factor for PD [28],
which have been linked to oxidative stress [29]. Metabolomics enables understanding how these
risk factors alter brain metabolism (i.e., neurons and astrocytes), and how dysregulated metabolism
is correlated with the onset and progression of PD [30].
Oxidative stress is a popular investigative target in CNS neurological disorders [31]. Oxidative
stress is regulated by metabolomic processes involving oxidative species and antioxidants.
Reactive oxygen species (ROS) include radical and non-radical compounds. ROS is generated
mainly through aerobic metabolism, but can be induced by other ion transferring reactions. At high
levels, ROS can damage lipids, proteins, and DNA [32]. However, ROS is also necessary and is
important for the regulation of signaling pathways, including apoptosis. ROS activities occur
through oxidation and reducing reactions [33]. ROS cellular levels are kept in balance with
antioxidants, one of the most important antioxidants is glutathione (GSH) [34]. Thus, oxidative
stress is an imbalance between pro-oxidants and antioxidants [35]. The resting brain consumes
about 20% of the body’s oxygen [36], which results in a high production of ROS. Accordingly,
the brain is highly susceptible to oxidative stress.
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1.3.2 Metabolomics in Food science
Food science studies the physical, biological, and chemical processes involved in food. This
includes determining the authenticity, contamination, nutritional content, quality, and safety of
food. Foods can be evaluated and compared by measuring levels of macro and micronutrients. The
amount of water, carbohydrates, proteins, and lipids will affect the flavor, structure and nutritional
content of food [37]. Metabolomics is a valuable tool to generate a chemical profile for different
foods. These chemical profiles will list the identification and quantification of key metabolites.
Alternatively, an entire spectrum may provide a chemical fingerprint. These chemical or
metabolomic profiles may be useful for the traceability of food or beverages, or for evaluating
quality [38]. This is particularly useful for high-cost items, such as honey, oil and wine, where
authentication is useful to avoid or prevent fraud [39].
For plant-based beverages, a major factor impacting the quality and value of the product are the
environment and the weather. Essentially identical food crops grown in different regions will
exhibit a locality-specific metabolite profile. Accordingly, the variable chemical composition will
impact the taste, smell and texture of the beverage. Wine, in particular, is often measured by the
quality of the grapes. To address this issue, metabolite levels were measured in grape pulp skins
and seeds from different regions of South Korea. A specific set of metabolites including sugars
and proline were observed to increase in areas with high sun exposure and lower water levels.
There was also a decrease of malate, citrate, and alanine [40]. Notably, these metabolomic
differences extended to all stages of grape development. 1H NMR was used to identify region
specific isopentanol and isobutanol compounds from wines and grapes from regions in Rioja [41].
The processing of the grapes also impacts the wine’s metabolome. For example, during
fermentation, yeast consumes sugars and produce a variety of metabolites. Different strains of
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yeast produced variable levels of succinate and glycerol [42]. Thus, metabolomics may help
monitor and analyze the fermentation processes and asses its quality and verify its origin. A change
in a metabolomics profile may easily identify the substitution of a cheaper, lower quality vintage
or type of wine for a higher priced product [43]. Metabolomic studies follow a general protocol as
outlined in figure 1.2. From a given biological sample, metabolites are extracted. Once extracted,
the metabolites are identified and quantified. The resulting data is than analyzed and evaluated,
typically with univariate and multivariate statistical methods.

1.4 Protocols and Procedures

Figure 1.2: The metabolomic process from sample collection to biological interaction.
Samples can be collected from a wide variety of sample types.

1.4.1 Sample Collection and Processing
Metabolomics requires the collection of all the available metabolites from a biological sample to
provide a complete view of the state of the system. Metabolite extraction is a very important step
of the protocol since it determines what parts of the metabolome are studied [44]. Thus,
metabolomics requires specialized and targeted extraction techniques to ensure the preservation of
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the metabolites and the prevention of chemical (e.g., oxidation, degradation, etc.) or enzymatic
transformation. An efficient extraction protocol is fast with minimal sample preparation. Minimal
sample preparation is typically needed for samples that are already in a liquid state. Conversely,
solid tissues or cells are typically subjected to sample homogenization or mechanical cell lysis
[45]. The quenching of biochemical reactions is also necessary to obtain a correct view of the
metabolome at the time of extraction. Different extraction procedures will highlight or emphasize
different biochemical pathways as well as impacting the percentage of each metabolite
successfully extracted [46]. In addition to chemical stability, physical properties such as solubility
and polarity will drastically impact which metabolites are maintained for a given extraction
solvent. Methanol and/or water will extract polar metabolites, such as amino acids. Chloroform
and/or methanol will extract nonpolar metabolites [47], while dichloromethane and methanol has
been used for lipid extraction [48]. Given these physical-chemical constraints, it is not possible to
harvest the entire metabolome utilizing a single extraction technique. Instead, extraction methods
typically focus on collecting a specific subset of the metabolome. Multiple subsets of metabolites
can be extracted with repeated extractions [49]. An additional goal of the extraction process is to
remove biomolecules while preserving the metabolites of interest. Reducing error and variability
is key to choosing an optimized extraction protocol.
Metabolites comprise a very diverse set of molecules that includes amino acids, vitamins, and
polyols. Accordingly, metabolites exhibit a wide range of chemical stability, and are variably
susceptible to changes in temperature, pH, ionic strength, oxidation and enzymatic activity.
Furthermore, the type of biological sample, such as a cell lysate or a urine sample, may also
differentially impact the chemical stability and the detection of specific metabolites. Sample
transport and storage is important concern since many human clinical samples cannot be tested as
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soon as collected. Most investigations of the impact of storage conditions on metabolite stability
recommend storage of samples at or below –20°C to preserve as many metabolites as possible
[50]. Freezing of the samples preserves the greatest number of metabolites. However, there is some
degradation during an extended storage of more than 5 years [51]. Notably, amino acids are more
prone to degradation compared to other metabolites [52]. Before samples are collected it is
important to consider how samples will be processed and stored.
Once the metabolome is collected, the metabolites need to be quantified and identified. Nuclear
magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) are the analytical methods
ordinarily used to characterize a metabolomics sample. Both methods have inherent strengths and
weaknesses in regards to their ability to quantify and analyze different samples and detect different
metabolites.
MS is highly versatile and is used in a majority of metabolomic studies. MS detects ions based on
their mass to charge ratio, which is used to quantify and identify metabolites and fragments based
on their known mass. An advantage of MS is its highly sensitive and universal detection of all
ionizable metabolites. Sensitivity and selectivity of the mass spectrometry experiment is
determined by the detection method. Mass spectrometers can be single or tandem instruments.
Triple-quadrupole and triple-quadrupole ion trap MS are highly sensitive and are typically used in
experiments where specific metabolites are targeted. Quadrupole-time of flight, linear-quadrupole
ion trap-orbitrap, and Fourier transform ion cyclotron resonance are typically used for global
profiling [53].
While MS can detect and identifying multiple metabolites, the use of chromatographic separation
helps avoid ion-suppression and addresses the low-mass range of metabolites. Of course, matrix
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effects may still interfere with the detection of the metabolites [54]. Liquid chromatography and
gas chromatography are the most common chromatographic techniques used in metabolomics. Gas
chromatography provides high separation and is less prone to ion suppression, but often requires
chemical modification to form ions in the gas phase [55]. Liquid chromatography does not require
chemical modification, but may still modulate the composition of the metabolome due to variable
recovery of the metabolite from the column, metabolite decomposition or chemical modification,
or ion-suppression due to co-eluting matrix compounds [56].
Ionization occurs typically after separation and is key for metabolite detection and quantification.
Electron impact is common for GC-MS. It is a harder ionization method and tends to lead to sample
fragmentation; however, it tends to avoid matrix effects [54]. Electrospray ionization is commonly
used in LC-MS. It is a softer technique and is less prone to fragmentation, but ion suppression is
common. Ion suppression occurs when charges on some molecules are lost due to the presence of
endogenous compounds that are more efficient in acquiring a charge. This negatively impacts the
reproducibility and accuracy of the metabolomics experiments. Ion suppression can be reduced
during experimentation design through extraction of only molecules of interest or separating
potentially competing molecules [57]. The use of multiple ionization methods has been suggested
to expand the number of detectable metabolites. [58]
Mass to charge ratio is used to identify the metabolite. However, the reliably identification of
metabolites by exact mass alone is challenging given the narrow mass distribution of metabolites
and the fact that a large number of molecules have the same molecular formula and mass.
Combining exact mass with retention time may improve the accuracy of metabolite identification.
Chromatography provides the experimental retention times. Software programs, such as Progensis
QI, are routinely used to identify metabolites based on mass and retention time. However, manual
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confirmation of metabolites is necessary to avoid misidentification with molecules with similar
mass and retention time. MS/MS fragmentation patterns can be matched with data from the PRIMe
website (http://prime.psc.riken.jp/) to further improve the assignment confidence [59].
Nuclear Magnetic Resonance (NMR) is also widely used in metabolomics. NMR detects the
absorbance of radio-frequency (RF) energy by specific nuclei in a magnetic field. NMR can detect
RF absorbance by 1H, 13C, and 31P nuclei. NMR samples require minimal sample preparation. This
is often limited to adding a deuterated buffer or solvent, and an internal standard. NMR chemical
shift standards include sodium trimethylsilylpropanesulfonate (DSS), 3-(Trimethylsilyl)propionic2,2,3,3 acid sodium salt (TMSP), and trimethylsilylpropanoic acid (TSP), which are also critical
for quantitation [60]. Buffers are used sample-dependent pH variations, which is a common
problem for clinical samples. For example, a phosphate buffer is typically added to urine samples
to maintain a pH of 7.
The most common NMR experiment used in metabolomics detects protons or 1H. 1H is an NMR
active nuclei, is a very common atom in organic molecules, and has a natural abundance of 99.98%.
NMR experiment acquisition time is directly proportional to the desired sensitivity. For 1H NMR
metabolic experiments, high sensitivity or signal-to-noise (S/N) can be obtained with acquisition
times of 5 minutes or less. Conversely, the natural abundance of
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C is only 1.1% requiring

significantly longer experimental times (> hours) to achieve the same relative S/N. Despite 100%
natural abundance, 31P NMR experiments are not as common, but are increasing in popularity. For
example, phosphorylation is important in various biological reactions that include glycolysis [61].
Metabolomics typically rely on one-dimensional (1D) 1H NMR experiments or two-dimensional
(2D) 1H-13C correlated experiments. 1D NMR experiments allow for easy quantification of
metabolites as intensities are directly correlated with metabolite concentrations. 2D NMR
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experiments, while more time consuming, allow for easy identification of metabolites by utilizing
multiple correlated chemical shifts. NMR is not as sensitive as MS, but can detect metabolites with
concentrations as low as ~ 3 M. NMR also requires a larger sample volume, typically from 500
L, for common 5 mm NMR tube, to 35 L for a 1.7 mM NMR tube.
Metabolite identification is accomplished by matching experimental chemical shifts to chemical
shifts from standard spectra in NMR databases. For example, the ECMDB (Escherichia coli
metabolome database, http://www.ecmdb.ca) is a compressive database that contains information
about the genome and metabolome of E. coli. The database contains 3760 compounds [62].
Chemical shifts are very sensitive to variations in the chemical environment, such as differences
in pH, ionic strength and temperature. Accordingly, databases routinely contain chemical shifts
collected at a pH of 7 and a temperature of 25 oC. Thus, an improvement in assignment accuracy
is obtained by matching the databases’ experimental parameters. Nevertheless, a chemical shift
error tolerance of 0.05 and 0.5 ppm is commonly required for 1H and
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C chemical shifts,

respectively.

1.4.2 Statistical Analysis of Metabolomics Data
Once NMR or MS spectra have been successfully collected, the data set is subjected to a variety
of statistical analysis to identify the underlying metabolic differences. Typical data analysis
methods focus on observing patterns in multivariate data sets. Proper data analysis requires
extracting the significant spectral data that defines the group separation while accounting for nonbiological sources of variance. Cell growth or sample collection, as well as sample preparation and
data collection can introduce variation and bias in the data set. Clinical samples have intrinsically
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large biological variations due to numerous factors such as age, diet, ethnicity, gender, physical
activity, race, and weight.
Principal component analysis (PCA), partial least squares regression (PLS), and orthogonal
projections to latent structures (OPLS) are multivariate statistical models commonly used in
metabolomics. PCA is an unsupervised technique, where sample group membership is not
identified. OPLS and PLS are supervised techniques where group membership is defined. As a
result, OPLS and PLS suffer from over-fitting the data and require extensive validation of the
resulting models. These multivariate statistics methods identify class separation by reducing data
to a few components and determining the source of the variance in the data set. The goal is to
identify changes in metabolite levels in response to a treatment or stressor. PCA is primarily used
to identify without bias the presence of group separation or variance in the data. OPLS is used to
identify the spectral signals or metabolites that define the group-based variation.
After a statistical model is generated, it is important to validate the model. Without proper
validation, erroneous metabolic perturbations may be improperly assigned to falsely differentiated
groups. Model quality and validation is commonly assed using R2, Q2, and p-values. R2 (ranges
from 0 to 1) is the measure of the degree of fit to the data. Q2 (ranges from 0 to 1) is a quality
assessment corresponding to the measure of the degree of fit for the data left out. A p-values <
0.05 from CV-ANOVA or a cross-permutation test provide model validation [63]. In practice,
good PCA or OPLS models yield extremely small p-values, much lower than 0.001.

1.5 Summary of Work
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Chapter 2 provides a detailed description of the metabolomics protocol developed and employed
to investigate PD and other neurodegenerative diseases. The protocol provides a detailed step-bystep description for acquiring metabolomics data from human cell cultures and mouse brain
tissues. The protocol includes the step by step direction for NMR and MS metabolite collection
and analysis. It also illustrates several statistical analysis methods for both multivariate and
univariate approaches. The chapter also covers the process of metabolite identification, a key step
to understand what cellular process were altered. Finally, it includes guides on univariate and
multivariate statistical methods and ways to validate significance.
Chapter 3 focuses on the effect of xenobiotic arsenic, a common metalloid associated with
Parkinson’s’ disease. Cultured astrocytes were treated with and without arsenic to evaluate
changes in cellular metabolism, especially in regards with glycolysis. Arsenic treatment was
observed to induce the production of potentially neurotoxic glutamate and a reduction in lactate
and citrate. Glycolysis may be upregulated to produce glutamate for glutathione (GSH), and as a
byproduct disrupted the production of other metabolites.
Chapter 4 examined the effect of different environments on grapes used in Pinot Noir wine.
Untargeted 1D 1H NMR metabolomics and a targeted differential sensing (DS) array were
combined to characterize the chemical profile of Pinot Noir wines due to different environments.
Each wine was differentiated by variable combinations of NMR and assay features. The NMR data
provided a comprehensive coverage of the metabolome, while the DS array targeted phenolic
compounds. Thus, the DS assay and the NMR data likely detect a distinct set of metabolites and
provided a complementary characterization of the wines.

16

1.6 References
1.

Morozova, O. and M.A. Marra, Applications of next-generation sequencing technologies

in functional genomics. Genomics, 2008. 92(5): p. 255-64.
2.

Morton, C.C., Genetics, genomics and gene discovery in the auditory system. Human

Molecular Genetics, 2002. 11(10): p. 1229-1240.
3.

Lowe, R., et al., Transcriptomics technologies. PLoS Comput Biol, 2017. 13(5): p.

e1005457.
4.

Gershon, D., proteomics technologies: Probing the proteome. Nature, 2003. 424(6948): p.

581-583.
5.

Graves, P.R. and T.A. Haystead, Molecular biologist's guide to proteomics. Microbiol

Mol Biol Rev, 2002. 66(1): p. 39-63; table of contents.
6.

Oliver, S.G., et al., Systematic functional analysis of the yeast genome. Trends

Biotechnol, 1998. 16(9): p. 373-8.
7.

DeBerardinis, R.J. and C.B. Thompson, Cellular metabolism and disease: what do

metabolic outliers teach us? Cell, 2012. 148(6): p. 1132-44.
8.

Raamsdonk, L.M., et al., A functional genomics strategy that uses metabolome data to

reveal the phenotype of silent mutations. Nature Biotechnology, 2001. 19(1): p. 45-50.
9.

Putri, S.P., et al., Current metabolomics: Practical applications. Journal of Bioscience and

Bioengineering, 2013. 115(6): p. 579-589.

17

10.

Trowell, H.C., Ants distinguish diabetes mellitus from diabetes insipidus. British medical

journal (Clinical research ed.), 1982. 285(6336): p. 217-217.
11.

Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 2010. 33(Supplement

1): p. S62-S69.
12.

Robertson, G.L., Diabetes Insipidus. Endocrinology and Metabolism Clinics of North

America, 1995. 24(3): p. 549-572.
13.

Monteiro, M.S., et al., Metabolomics analysis for biomarker discovery: advances and

challenges. Curr Med Chem, 2013. 20(2): p. 257-71.
14.

Graham, S.F., et al., Investigation of the Human Brain Metabolome to Identify Potential

Markers for Early Diagnosis and Therapeutic Targets of Alzheimer’s Disease. Analytical
Chemistry, 2013. 85(3): p. 1803-1811.
15.

Serkova, N.J., T.J. Standiford, and K.A. Stringer, The emerging field of quantitative

blood metabolomics for biomarker discovery in critical illnesses. Am J Respir Crit Care Med,
2011. 184(6): p. 647-55.
16.

Wishart, D.S., et al., The human cerebrospinal fluid metabolome. J Chromatogr B Analyt

Technol Biomed Life Sci, 2008. 871(2): p. 164-73.
17.

Psychogios, N., et al., The human serum metabolome. PLoS One, 2011. 6(2): p. e16957.

18.

Yabroff, K.R., et al., Economic burden of cancer in the United States: estimates,

projections, and future research. Cancer Epidemiol Biomarkers Prev, 2011. 20(10): p. 2006-14.

18

19.

Ward, Patrick S. and Craig B. Thompson, Metabolic Reprogramming: A Cancer

Hallmark Even Warburg Did Not Anticipate. Cancer Cell, 2012. 21(3): p. 297-308.
20.

Warburg, O., On the origin of cancer cells. Science, 1956. 123(3191): p. 309-14.

21.

Mathupala, S.P., Y.H. Ko, and P.L. Pedersen, The pivotal roles of mitochondria in

cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochimica et
Biophysica Acta (BBA) - Bioenergetics, 2010. 1797(6): p. 1225-1230.
22.

Chaudhuri, K.R., et al., Non-motor symptoms of Parkinson's disease: diagnosis and

management. Lancet Neurol, 2006. 5(3): p. 235-45.
23.

Varanese, S., et al., Treatment of advanced Parkinson's disease. Parkinsons Dis, 2011.

2010: p. 480260.
24.

Kowal, S.L., et al., The current and projected economic burden of Parkinson's disease in

the United States. Movement Disorders, 2013. 28(3): p. 311-318.
25.

Jankovic, J., et al., The Evolution of Diagnosis in Early Parkinson Disease. JAMA

Neurology, 2000. 57(3): p. 369-372.
26.

Murman, D.L., Early treatment of Parkinson's disease: opportunities for managed care.

Am J Manag Care, 2012. 18(7 Suppl): p. S183-8.
27.

Goldman, S.M., Environmental toxins and Parkinson's disease. Annu Rev Pharmacol

Toxicol, 2014. 54: p. 141-64.
28.

Gorell, J.M., et al., Multiple risk factors for Parkinson's disease. Journal of the

Neurological Sciences, 2004. 217(2): p. 169-174.

19

29.

Chen, P., M.R. Miah, and M. Aschner, Metals and Neurodegeneration. F1000Res, 2016.

5.
30.

Powers, R., et al., Metabolic Investigations of the Molecular Mechanisms Associated

with Parkinson's Disease. Metabolites, 2017. 7(2).
31.

Patel, M., Targeting Oxidative Stress in Central Nervous System Disorders. Trends

Pharmacol Sci, 2016. 37(9): p. 768-778.
32.

CROSS, C.E., et al., Oxygen Radicals and Human Disease. Annals of Internal Medicine,

1987. 107(4): p. 526-545.
33.

Ray, P.D., B.W. Huang, and Y. Tsuji, Reactive oxygen species (ROS) homeostasis and

redox regulation in cellular signaling. Cell Signal, 2012. 24(5): p. 981-90.
34.

Wilson, J.X., Antioxidant defense of the brain: a role for astrocytes. Can J Physiol

Pharmacol, 1997. 75(10-11): p. 1149-63.
35.

Jones, D.P., Redefining Oxidative Stress. Antioxidants & Redox Signaling, 2006. 8(9-

10): p. 1865-1879.
36.

Mink, J.W., R.J. Blumenschine, and D.B. Adams, Ratio of central nervous system to

body metabolism in vertebrates: its constancy and functional basis. American Journal of
Physiology-Regulatory, Integrative and Comparative Physiology, 1981. 241(3): p. R203-R212.
37.

Pomeranz, Y., Functional properties of food components. 2nd ed. Food science and

technology. 1991, San Diego: Academic Press. ix, 569 p.

20

38.

Castro-Puyana, M., et al., Application of mass spectrometry-based metabolomics

approaches for food safety, quality and traceability. TrAC Trends in Analytical Chemistry, 2017.
93: p. 102-118.
39.

Ogrinc, N., et al., The application of NMR and MS methods for detection of adulteration

of wine, fruit juices, and olive oil. A review. Analytical and Bioanalytical Chemistry, 2003.
376(4): p. 424-430.
40.

Son, H.-S., et al., Metabolomic Studies on Geographical Grapes and Their Wines Using

1H NMR Analysis Coupled with Multivariate Statistics. Journal of Agricultural and Food
Chemistry, 2009. 57(4): p. 1481-1490.
41.

López-Rituerto, E., et al., Investigations of La Rioja Terroir for Wine Production Using

1H NMR Metabolomics. Journal of Agricultural and Food Chemistry, 2012. 60(13): p. 34523461.
42.

Son, H.-S., et al., 1H NMR-Based Metabolomic Approach for Understanding the

Fermentation Behaviors of Wine Yeast Strains. Analytical Chemistry, 2009. 81(3): p. 11371145.
43.

Fotakis, C., et al., NMR metabolite fingerprinting in grape derived products: An

overview. Food Research International, 2013. 54(1): p. 1184-1194.
44.

Mushtaq, M.Y., et al., Extraction for metabolomics: access to the metabolome.

Phytochem Anal, 2014. 25(4): p. 291-306.

21

45.

Beckonert, O., et al., Metabolic profiling, metabolomic and metabonomic procedures for

NMR spectroscopy of urine, plasma, serum and tissue extracts. Nature Protocols, 2007. 2(11): p.
2692-2703.
46.

Canelas, A.B., et al., Quantitative Evaluation of Intracellular Metabolite Extraction

Techniques for Yeast Metabolomics. Analytical Chemistry, 2009. 81(17): p. 7379-7389.
47.

Sapcariu, S.C., et al., Simultaneous extraction of proteins and metabolites from cells in

culture. MethodsX, 2014. 1: p. 74-80.
48.

Bligh, E.G. and W.J. Dyer, A Rapid Method Of Total Lipid Extraction and Purification.

Canadian Journal of Biochemistry and Physiology, 1959. 37(1): p. 911-917.
49.

Coman, C., et al., Simultaneous Metabolite, Protein, Lipid Extraction (SIMPLEX): A

Combinatorial Multimolecular Omics Approach for Systems Biology. Molecular & cellular
proteomics : MCP, 2016. 15(4): p. 1453-1466.
50.

Rotter, M., et al., Stability of targeted metabolite profiles of urine samples under different

storage conditions. Metabolomics : Official journal of the Metabolomic Society, 2017. 13(1): p.
4-4.
51.

Haid, M., et al., Long-Term Stability of Human Plasma Metabolites during Storage at

−80 °C. Journal of Proteome Research, 2018. 17(1): p. 203-211.
52.

Breier, M., et al., Targeted metabolomics identifies reliable and stable metabolites in

human serum and plasma samples. PLoS One, 2014. 9(2): p. e89728.
53.

Gowda, G.A. and D. Djukovic, Overview of mass spectrometry-based metabolomics:

opportunities and challenges. Methods Mol Biol, 2014. 1198: p. 3-12.

22

54.

Smeraglia, J., S.F. Baldrey, and D. Watson, Matrix effects and selectivity issues in LC-

MS-MS. Chromatographia, 2002. 55(1): p. S95-S99.
55.

Sparkman, O.D., Z. Penton, and F.G. Kitson, Gas chromatography and mass

spectrometry : a practical guide. 2011.
56.

Vuckovic, D., Current trends and challenges in sample preparation for global

metabolomics using liquid chromatography–mass spectrometry. Analytical and Bioanalytical
Chemistry, 2012. 403(6): p. 1523-1548.
57.

Furey, A., et al., Ion suppression; a critical review on causes, evaluation, prevention and

applications. Talanta, 2013. 115: p. 104-22.
58.

Nordström, A., et al., Multiple Ionization Mass Spectrometry Strategy Used To Reveal

the Complexity of Metabolomics. Analytical Chemistry, 2008. 80(2): p. 421-429.
59.

Sawada, Y., et al., Widely Targeted Metabolomics Based on Large-Scale MS/MS Data

for Elucidating Metabolite Accumulation Patterns in Plants. Plant and Cell Physiology, 2008.
50(1): p. 37-47.
60.

Rundlöf, T., et al., Survey and qualification of internal standards for quantification by 1H

NMR spectroscopy. Journal of Pharmaceutical and Biomedical Analysis, 2010. 52(5): p. 645651.
61.

Duboc, D., et al., Phosphorus NMR spectroscopy study of muscular enzyme deficiencies

involving glycogenolysis and glycolysis. Neurology, 1987. 37(4): p. 663-663.
62.

Sajed, T., et al., ECMDB 2.0: A richer resource for understanding the biochemistry of E.

coli. Nucleic Acids Res, 2016. 44(D1): p. D495-501.

23

63.

Eriksson, L., J. Trygg, and S. Wold, CV-ANOVA for significance testing of PLS and

OPLS® models. Journal of Chemometrics, 2008. 22(11‐12): p. 594-600.

24

Chapter 2
2. Metabolomics Analyses from Tissues in Parkinson’s disease
2.1 Introduction
Parkinson’s disease (PD), the second most common neurodegenerative disorder worldwide, is
characterized by the selective loss of dopaminergic neurons of the substantia nigra pars compacta
(SNpc) [1]. There is no current treatment to stop neuronal cell death progression or to cure PD.
Thus, to find neuroprotective strategies, a clear understanding of the mechanism(s) involved in
dopaminergic cell death is needed. Mitochondrial dysfunction and the concomitant alterations in
redox homeostasis and bioenergetics (energy failure) are thought to be a central component of PD
[2-4]. One means of analyzing the state of a biological system is by monitoring the metabolome,
i.e., all the metabolites present in a cell, biofluid, tissue, organ, or organism [5, 6]. In this regard,
metabolomics is the study of the changes in the concentration and the identity of these metabolites
that result from environmental or genetic stress, or from a disease state or drug treatment. A better
understanding of the biological phenotype during disease development and progression may be
achieved by identifying and quantifying variations in metabolite levels. In essence, metabolomics
provides a top-down view of complex biological systems. Accordingly, metabolomics has evolved
to become an important resource for systems biology and a valuable tool to study disease states
[7]. Metabolomics has been successfully applied to study neurological and neurodegenerative
disorders [8]. Indeed, previous studies have demonstrated the applicability of metabolomics in: 1)
the identification of potential biomarkers of PD diagnosis, onset and progression [9-11]; 2) the
identification of novel mechanisms of disease progression [12-15]; and 3) the assessment of
treatment prognosis and outcome [16]. Using metabolomics, we and others have established a link
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between the alterations in central carbon metabolism induced by PD risk factors, redox
homeostasis and bioenergetics and their contribution to the survival or death of dopaminergic cells
[2].
Unlike other OMICs techniques, the composition of the metabolome can easily change from the
processing, handling and storage of samples [17]. Metabolites may chemically transform or
degrade due to residual enzymatic activity, from oxidation, from low chemical stability, or from
other chemical activity. Thus, robust and reproducible isolation of metabolites is a key step in the
metabolomics workflow. Univariate and multivariate statistical analysis are also an important
aspect of a metabolomics study [18]. But, the incorrect application of statistical techniques, the
insufficient preprocessing, the lack of proper model validation, or the over-interpretation of models
and outcomes are all common concerns that often lead to erroneous or misleading biological
insights from metabolomics data [18]. Metabolomics has commonly relied on mass spectrometry
(MS) [19] or nuclear magnetic resonance (NMR) [20] as the primary analytic source for sample
analysis. Again, a successful metabolomics investigation is dependent on appropriate protocols for
data collection, processing and analysis. To address these issues, we have provided a detailed, stepby-step description of a metabolomics workflow specifically applicable to the analysis of brain
cell cultures and tissues used in our research using PD-experimental models (see Figure 2.1). We
describe methods to assist in the efficient cell culturing, metabolite extraction, and data collection
and analyses. Alongside, we discuss a combined NMR and MS approach to improve metabolome
coverage, which allows for the identification of key neurological metabolites. While the protocols
outlined in this chapter have been developed using PD-experimental models, most of the
methodology may be universally applied to any metabolomics study.
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Figure 2.1: A schematic diagram is shown that outlines the overall metabolic workflow used in
the analysis of brain cell cultures and tissues from experimental PD-models. Only the major
protocol steps are highlighted in the flow diagram. The figure was generated using free medical
images from Servier Medical Art (https://smart.servier.com/) under the Creative Commons
License Attribution 3.0 Unported (CC BY 3.0).

2.2 Materials
Prepare all aqueous solutions and buffers with either Nanopure H2O or deuterated water (D2O).
Please follow all safety regulations in regards to handling biological samples and the disposal of
both chemical and biological waste. A valuable rule-of-thumb in the handling of all tissues,
biofluids (e.g., blood, urine, etc.) and cell lines is to assume a contamination with a virus, pathogen
or toxin and to handle the samples accordingly.
2.2.1 Laboratory Equipment
1. Bruker AVANCE III HD 700 MHz NMR spectrometer equipped with a 5 mm quadruple
resonance QCI-P cryoprobe (1H, 13C, 15N, and 31P) with z-axis gradients, an automatic tune
and match system (ATM), and a SampleJet automated sample changer system with Bruker
ICON-NMR software (Bruker Biospin, Billerica, MA)
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2. Synapt G2 HDMS quadrupole time-of-flight (TOF) MS instrument equipped with an ESI
source (Waters, Milford, MA).
3. Waters ACQUITY M-class Xevo G2-XS QToF MS instrument equipped with an ESI
source (Waters, Milford, MA).
4. BSL-2 biosafety level grade hood (e.g., Biological Safety Cabinet, LF BSC class 2 type A,
Thermo Fischer Scientific, Waltham, MA).
5. Nanopure ultra water system (Barnstead Inc., Dubuque, IA)
6. Lab Armor bead bath (Chemglass Life Sciences, Vineland NJ)
7. Incubator capable of maintaining physiological temperature and proper carbon dioxide
levels (e.g., HERA CELL VIOS 250i CO2 Incubator, Thermo Fischer Scientific, Waltham,
MA).
8. pH meter and probe
9. Refrigerated centrifuge capable of speeds up to 13000 rpm (e.g., SORVALL micro 21R
centrifuge, Thermo Fischer Scientific, Waltham, MA).
10. Speed Vac for solvent removal (e.g., SAVANT SC210A SpeedVac concentrator, Thermo
Fischer Scientific, Waltham, MA)).
11. Freeze dryer to remove water (e.g., FreeZone 4.5, LABCONCO, Kansas City, MO)).
12. 1000 µL to 1 µL pipettes
13. FastPrep-96 homogenizer (MP Biomedicals, Santa Ana, CA) for brain tissue analysis, uses
Lysing Matrix D.
14. ACCU-SCOPE 3030ph microscope (Commac, NY)
15. cryogenic storage container (Taylor Wharton, Theodor, Al)
16. -80°C freezer
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2.2.2 Disposable supplies
1. 1 mL to 1 L pipette tips
2. 10 mL aspirating pipettes
3. 15 mL Falcon tubes
4. 2 mL Eppendorf tubes
5. 1 mL screw-cap microcenterfuge tubes
6. LC-MS certified total recovery vial (Waters, Milford, MA)
2.2.3 Isotopically labeled solvents and reagents (see Notes 1 and 2)
1. Deuterium oxide (D2O, 99.8 atom %D)
2. 3-(trimethylsilyl) propionic-2,2,3,3-d4 acid sodium salt (TMSP-d4, 99.8 atom % D)
3. Dimethyl sulfoxide-d6 (DMSO-d6, 99.8 atom %D
4.
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C6-glucose (99% 13C)

5.
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C2-acetate (99% 13C)

6. Other potential 13C-carbon labeled or 15N-nitrogen labeled reagents

2.2.4 Buffers
1. Wash buffer, phosphate-buffered saline (PBS) at pH 7.4: 137 mM NaCl, 2.7 mM KCl, 10
mM Na2HPO4 and 2 mM KH2PO4. To prepare 1 L PBS buffer at pH 7.4, add 8.0 g of NaCl,
0.2 g of KCl, 2.68 g of Na2HPO4.7H20 and 0.24 g of KH2PO4 to a final volume of 1 L of
Nanopure water.
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2. NMR buffer: 50 mM phosphate buffer at pH 7.2 (uncorrected, see Note 3) in 600 μL of
99.8% D2O. Add 50 μM (one-dimensional [1D] NMR experiment) or 500 μM (twodimensional [2D] NMR experiment) TMSP-d4 as an internal chemical shift reference.
3. MS extraction buffer: Mix 20 mL LC-MS grade water with 80 mL LC-MS grade methanol.
Store at –40°C.
4. MS reconstitution solution: LC-MS grade water with 0.1% LC-MS grade formic acid.
5. LC mobile phase A: LC-MS grade water with 0.1% LC-MS grade formic acid.
6. LC mobile phase B: LC-MS grade acetonitrile/methanol with 0.1% LC-MS grade formic
acid.

2.2.5 Cell lines and media
1. For cell cultures, we have used human dopaminergic neuroblastoma cell lines such as SKN-SH (HTB-11, ATCC, Manassas, VA) [15], SH-SY5Y (CRL-2266, ATCC), N27
immortalized rat dopaminergic cells (SCC048, EMD Millipore, Temecula, CA) [31],
human immortalized midbrain neuronal precursors LUHMES (CRL-2927, ATCC) and
primary rat/mouse astrocytes [32] following the specifications of the commercial providers
or published protocols.
2. Cell culture media and supplements are obtained from commercial vendors such as
GIBCO/Life Technologies (Grand Island, NY), Fisher Scientific, Hyclone (GE Healthcare,
Logan, UT) and Atlanta Biologicals (Flowery Branch, GA).
2.2.6 Software and Databases
1. Bruker ICON-NMR software for automated NMR data acquisition (Bruker Biospin,
Billerica, MA).
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2. MVAPACK metabolomics toolkit for processing and analyzing chemometric data
(http://bionmr.unl.edu/mvapack.php) [21].
3. PCA/PLS-DA utilities for quantifying separation in PCA, PLS-DA and OPLS-DA scores
plots (http://bionmr.unl.edu/pca-utils.php) [22].
4. NMRPipe

software

for

processing

and

visualizing

NMR

data

(https://www.ibbr.umd.edu/nmrpipe/install.html) [23].
5. NMRViewJ software for processing and visualizing NMR data (One Moon Scientific, Inc.
Westfield, NJ; https://nmrfx.org/) [24].
6. MassLynx V4.1(Waters Corp., Milford, MA) for mass spectral data processing
(http://www.waters.com/waters/en_US/MassLynx-Mass-Spectrometry-Software/nav.htm?locale=en_US&cid=513164).
7. Progenesis QI (version 2.0, Nonlinear Dynamics, Newcastle, UK) for processing and
analysis of LC-MS data (http://www.nonlinear.com/progenesis/qi/)
8. R statistical package (https://www.r-project.org/) [25].
9. Chenomx (Chenomx, Inc., Edmonton, AB, Canada) software for automated metabolite
assignment and quantification from 1D 1H NMR spectra (https://www.chenomx.com/).
10. Mzmine software (http://mzmine.github.io/download.html) for metabolite identification
from MS data [26].
11. MetaboAnalyst software for the statistical, functional and integrative analysis of
metabolomics data (http://www.metaboanalyst.ca/) [26].
12. ChemSpider chemical structure database http://www.chemspider.com/ [27].
13. Human Metabolomics Database (HMDB) of reference NMR and mass spectral data for
known metabolites (http://www.hmdb.ca/) [28].
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14. Biological Magnetic Resonance Data Bank (BMRB) of reference NMR data for known
metabolites http://www.bmrb.wisc.edu/metabolomics/) [29].
15. Non-uniform schedule (NUS) generator (http://bionmr.unl.edu/dgs-gensched.php) for
NUS NMR data acquisition [30].

2.3 Methods
2.3.1 Experimental PD models
The etiology of PD has yet to be clearly established. The major risk factor identified for PD is
aging as its prevalence and incidence increases exponentially from ages 65 to 90 [31]. A fraction
of PD occurrence (~10%) is related to mutations in genes such as those encoding α-synuclein
(SNCA/PARK1-4), DJ-1 (PARK7), PTEN-induced putative kinase 1 (PINK1/PARK6), leucine-rich
repeat kinase 2 (LRRK2/PARK8) and parkin (PARK2) [32, 33]. However, over 85% of PD occurs
in a sporadic (idiopathic) form without a clearly defined genetic basis. Epidemiological studies
suggest that lifestyle, occupational and environmental exposures can increase the risk of
developing PD [34-36]. Thus, it is thought that PD arises from the convergence of genetic
susceptibility, environmental exposures, and aging.
Cellular and animal disease models based on both genetic-, toxin- or stress-induced
neurodegeneration have been used to understand PD pathogenesis [35, 37] (see Figure 2.2.
However, not all experimental models recapitulate all PD hallmarks in their entirety. Genetically
engineered PD mouse models have been developed for the overexpression of mutant genes [35,
33]. However, only marginal or null dopaminergic cell death has been observed in genetic-based
animal models. Recent advances in mammalian genome engineering technology have led to the
generation of rat PD models that seem to better reproduce PD hallmarks including progressive loss
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of dopaminergic neurons, locomotor behavior deficits, and age-dependent formation of abnormal
α-synuclein protein aggregates (Lewy bodies) [38].

Figure 2.2: Common models of PD. (A) A summary of advantages and disadvantages of common
models of PD. (B) A List of some model specific characteristics observed for different PD models.
The figure was generated using free medical images from Servier Medical Art
(https://smart.servier.com/) under the Creative Commons License Attribution 3.0 Unported (CC
BY 3.0).
On the other hand, the use of mitochondrial/environmental toxins such as 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP, or its active metabolite 1-methyl-4-phenylpyridine MPP+) and
the pesticides rotenone and paraquat that induce dopaminergic cell death in vitro and in vivo, is
supported by clinical and epidemiological studies [35]. Several other toxicants, such as metals,
diverse pesticides, polychlorinated biphenyls, diet as well as inflammatory processes have been
implicated as PD risk factors [39, 40]. However, it is clear that not a single environmental exposure
is responsible for all PD cases nor are they the single cause for PD. Accordingly, new models
studying gene-environment interactions have also emerged.
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For the most part, experimental PD-models are design to reproduce one or more key aspects of PD
pathogenesis including: genetic modifications, mitochondrial dysfunction, oxidative stress,
accumulation of misfolded aggregates and impaired proteostatic processes, alterations in
dopamine metabolism and inflammation [35]. Experimental PD models have helped to identify
important mechanisms regulating dopaminergic cell death and survival, and they should continue
to enhance our understanding of PD pathogenesis. In our metabolomics investigations, we have
used neuronal-like cell cultures of neuroblastoma cells and immortalized midbrain dopaminergic
cells from rats and humans exposed to PD-related insults and gene-environment interactions. In
addition, we have also evaluated changes in the metabolome of mice exposed to pesticides and
heavy-metals liked to PD or parkinsonisms [41, 15]. The protocol described below is a general
protocol for isolating and characterizing changes in the metabolome applicable to different types
of cell cultures and brain.

2.3.2 Cell culture
Cell culture procedures must follow published guidelines to avoid misidentification and
contamination [42]. We recommend to start with one 100 mm2 dish of 90% confluent cells per
sample/replica, but if the metabolite is abundant enough, this can be reduced to a smaller sample
size.

For PD-related insults, cells can be treated with mitochondrial toxins (MPP+ or rotenone),
pesticides (paraquat or dieldrin) or the overexpression of PD-related genes (WT or mutant forms
of α-synuclein via viral vectors or conventional transfection procedures), as explained in our
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previous publications [41, 45]. The exact dose and time course must be determined empirically,
but we recommend to work with a dose that will induce cell death of ~50% within no less than 48
h as neurodegeneration is a slow process, and evaluate changes in the cellular metabolome prior
to any detection of cell death (~24 h of treatment) (see Note 4-6 for considerations in regards to
cell survivability, sample handling and randomization).

2.3.3 Unlabeled Metabolomics Sample Number/Replicas
Use the maximal number of replicates per group that is possible (see Note 7). A typical number of
replicate cultures per group is ten. Adjust the number of replicates given practical considerations,
such as the number of groups, but the number of replicates per group should not be below six.

2.3.4 Isotopically Labeled Metabolomics Samples
Identify the 13C-, 15N or other isotopically labeled tracer. The tracer should be in accordance to the
metabolic pathway of interest and expected to be affected by the experimental treatment.

13

C6 -

glucose is a common choice for a tracer since it highlights central carbon metabolism (glycolysis
and TCA cycle), but a variety of other tracers may be used. Equimolary supplement culture media
with the appropriate 13C-carbon labeled source. (see Note 8).

2.3.5. Extracting Water Soluble Metabolites from PD Cell Cultures
All samples should be kept on ice or at 4 oC during sample preparation or handling. Samples should
be stored at -80 oC, but, ideally, samples should be immediately analyzed. In addition to keeping
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samples cold, there are four other issues that are critical to the successful preparation of
metabolomics samples: (1) speed, (2) consistency, (3) random processing of samples, and (4) the
efficient removal of all biomolecules and cell debris [6]. The processing of all metabolomics
samples should proceed as quickly as possible while minimizing any loss in quality. Metabolites
can chemically degrade or transform within milliseconds due to enzymatic activity, oxidation,
chemical instability, or any number of other chemical processes [43]. Accordingly, rapidly
inactivating and removing all biomolecules and cell debris (usually through methanol/ethanol
precipitation) that may transform or bind a metabolite is a necessary step of the protocol (see Notes
9).
1. Collect 1 mL of the media for metabolomic analysis. In addition to the cell extract, the
media may should also be analyzed for metabolomics changes as many metabolites get
exchanged or effluxed outside of the cell. In this regards, the media is treated simply as
another cell extract.
2. Wash the cells twice with 5 mL of PBS to remove debris. Discard the wash.
3. Lyse and quench cells with 1 mL of pre-chilled methanol at -20 oC. Incubate cells at -80
°C for 15 min.
4. Using a cell scraper, detach and collect cell debris and methanol in a 2 mL microcentrifuge
tube. Confirm cell detachment using a microscope and repeat lyse and quenching if
necessary.
5. Centrifuge the 2 mL microcentrifuge tube for 5 min at 15,000 g and 4 °C to pellet the cell
debris.
6. Collect the supernatant and transfer to a new 2 mL microcentrifuge tube.

36

7. Repeat the metabolome extraction by adding 0.5 mL of an 80%/20% mixture of
methanol/water kept at -20°C to the cell pellet.
8. Centrifuge the cell pellet with the extraction solvent for 5 min at 15,000 g at 4 °C to pellet
the cell debris.
9. Collect the supernatant and transfer it to the 2 mL microcentrifuge tube containing the
original methanol extract. Combine the two extraction supernatants into a single tube.
10. Repeat the metabolome extraction a third time by adding 0.5 mL of ice cold water to the
cell pellet.
11. Centrifuge the cell pellet with the extraction solvent for 5 min at 15,000 g at 4 °C to pellet
the cell debris.
12. Collect the supernatant and transfer it to the 2 mL microcentrifuge tube containing the two
previous extraction supernatants. Combine the three extraction supernatants into a single
tube.
13. Split the sample into two 2 mL Eppendorf tube. Aliquot 100 L for MS analysis and the
remainder of the sample is used for NMR analysis.
14. Use a SpeedVac or a rotary evaporator to remove the methanol.
15. Flash-freeze the samples in liquid nitrogen.
16. Remove the water and bring to dryness using a lyophilizer.
17. Repeat steps 1 to 16 for each replicate and for each group (see Note 6).
18. Store samples in a -80 oC freezer or proceed to preparing the NMR and/or MS samples (see
sections 3.7 and 3.8).

2.3.6 Extracting Water Soluble Metabolites from Mouse Brain Tissue
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1. Similar to cell culture treatments, a number of experimental paradigms have been used to
model PD in vivo [35, 44]. We have used the subchronic exposure to pesticides and metals
[15], but the protocol described can be applied to all murine animal models.
2. We have successfully used 200 mg/kg of
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C6-glucose at a total volume of 100 µL

administered to fasted mice (overnight) via intra-orbital injection to label metabolites
extracted from mouse brain tissue (Figure 2.3).
3. Harvest and dissect the mice brain tissue (15 to 20 min after the injection of 13C-labeled
tracer if used, see Figure 2.3).
4. Transfer the tissue to a 2 mL microcentrifuge tube containing Lysing Matrix D and weigh
the amount of tissue harvested from the mice, and immediately freeze the tissue with liquid
nitrogen.
5. Extract the tissue with a 1:1 mixture of methanol and water prechilled to -20 oC. The
volume of the extraction solvent depends upon the weight of the tissue.
6. Homogenize the sample in a FastPrep with lysing Matrix D at 1300 rpm for 20 seconds,
and for two cycles.
7. Incubate the tissue at -80 oC for 10 min to extract the metabolome.
8. Centrifuge at 1000 g for 10 min at 4 oC to remove tissue debris
9. Collect the supernatant and transfer to a new 2 mL microcentrifuge tube.
10. Repeat the metabolome extraction by adding 0.7 ml of 1:1 mixture of methanol and water
prechilled to -20 oC to the tissue pellet.
11. Repeat steps 6 to 8 and combine the supernatant with the previous extract.
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12. Normalize the metabolomics sample to the tissue weight by diluting all of the samples to a
final volume of 1.5 mL. Add as much of a 1:1 mixture of methanol and water prechilled to
-20 oC as needed to achieve a final volume of 1.5 mL.
13. Split the sample into two 2 mL Eppendorf tube. Aliquot 100 L for MS analysis and the
remainder of the sample is used for NMR analysis.
14. Use a SpeedVac or a rotary evaporator to remove the methanol.
15. Flash-freeze the samples in liquid nitrogen.
16. Remove the water and bring to dryness using a lyophilizer.
17. Repeat steps 3 to 16 for each replicate and for each group (see Note 6).
18. Store samples in a -80 oC freezer or proceed to preparing the NMR and/or MS samples (see
sections 2.3.7 and 2.3.8).
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Figure 2.3: In vivo evaluation 13C6-glucose metabolism. Fasted mice (overnight) were
administered 13C-glucose (200 mg/kg body weight , 100 µl) via retro-orbital injection and
brain regions were dissected at the time indicated for NMR analysis.
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2.3.7 Preparation of NMR Samples
1. For one-dimensional (1D) NMR experiments, lyophilized cell-free lysates or tissue
extracts are suspended in 600 μL of 100% 50 mM D2O phosphate buffer (uncorrected pH
7.2) with 50 µM 3-(trimethylsilyl) propionic-2,2,3,3-d4 acid sodium salt (TMSP-d4)
2. For two-dimensional (2D) NMR experiments, lyophilized cell-free lysates or tissue
extracts are suspended in 600 μL of 100% 50 mM D2O phosphate buffer (uncorrected pH
7.2) with 500 µM TMSP-d4.
3. Centrifuge the sample at 14,000 g for 10 min to remove any particulates.
4. The sample is transferred to a 4” 5 mM SampleJet NMR tube with a pipette (see Note 10).
5. Repeat steps 1 to 4 for each replicate and for each group (see Note 6)
6. Each sample is added to a 96 well plate SampleJet configuration equilibrated to 4 °C to
prevent metabolite degradation (see Figure 2.4).
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Figure 2.4: High-throughput sample preparation. Images illustrating the loading of replicate
metabolomics samples into the (A) 96 well plate SampleJet configuration and (B) the LC-MS
autosampler.

2.3.8 Preparation of Mass Spectrometry Samples
1. Dissolve lyophilized cell-free lysates or tissue extracts in 20 µL of reconstitution solution
and vortex for 30 s.
2. Centrifuge the solution at 14,000 g for 10 min to remove any particulate matter.
3. Transfer the supernatant to LC vials and keep them in wet ice.
4. Repeat steps 1 to 3 for each replicate and for each group (see Note 6)
5. Prepare quality control (QC) samples by pooling a 1 L aliquot from each biological
sample and transferring to a new LC vial labeled as QC.
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6. Place all vials into the autosampler equilibrated to 4 °C to prevent metabolite degradation
(see Figure 2.4).

2.3.9 NMR Data Collection
All NMR experiments are conducted at 298 K using a Bruker AVANCE III HD 700 MHz
spectrometer equipped with a 5 mm quadruple resonance QCI-P cryoprobe (1H, 13C, 15N, and 31P)
with z-axis gradients. An automatic tune and match system (ATM), and a SampleJet automated
sample changer system with Bruker ICON-NMR software were used to automate the NMR data
collection (see Figure 2.5).
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Figure 2.5: High-throughput NMR data collection. ICONNMR screenshots illustrating the
stepwise workflow for setting-up a high-throughput 1D 1H NMR metabolomics screen.
2.3.9.1 1D 1H NMR
1. Load the NMR metabolomics samples into the SampleJet automated sample changer system
(see Figure 2.4). Check that the SampleJet is in the correct mode (i.e., 5 mm tubes)
2. Log into an account on the spectrometer workstation and start the Topspin software.
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3. The first NMR sample is lowered into the magnet using the Bruker command, sx 101, where
101 corresponds to sample one in rack one.
4. The spectrometer is locked onto the D2O solvent frequency using the Bruker command, lock
D2O.
5. The NMR sample is shimmed for optimal signal and suppression of the water signal by typing
the Bruker command topshim. This will initiate an automated gradient shimming procedure,
which may take a few min to complete (see Note 11).
6. The sample is automatically tuned and matched using the ATM system by typing the Bruker
command, atma.
7. The 90-degree pulse length (μs) is determined by measuring a null spectrum with an
approximate 360-degree pulse using the Bruker zg pulse sequence (see Note 12).
8. A 1D 1H NMR spectrum is obtained for each sample using a standard excitation sculpting
water suppression pulse program (Bruker zgesgp pulse sequence) that provides optimal
suppression of the residual water signal while maintaining a flat baseline (see Note 13).
9. Typical experimental parameters for a 1D 1H NMR spectrum obtained on a Bruker 700
MHz spectrometer with a cryoprobe correspond to 128 scans, 16 dummy scans, 32,768
data points, a spectral width of 11,160.7 Hz, and a relaxation delay of 1.5 (see Note 14).
10. Automated data collection of the entire set of metabolomics samples is accomplished using
Bruker ICONNMR 5 (see Figure 2.5).
11. The sample filename, solvent, pulse program and temperature parameters are all defined
in Bruker ICONNMR 5 (see Notes 15 to 17).
12. Collect the 1D 1H NMR spectrum for each replicate and each group (see Note 2.6).
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13. The data is processed initially with Topspin to verify spectral quality, but exported for
further analysis (see Figure 2.6A).

Figure 2.6: NMR metabolomics spectral data. Examples of a typical (A) 1D 1H NMR spectrum
and a (B) 2D 1H-13C HSQC spectrum acquired from PD metabolomics samples.
2.3.9.2 2D 1H-13C-HSQC NMR (see Note 18)
1. Follow steps 1 to 7 from section 3.9.1.
2. Using ICONNMR 5, the sample filename, solvent, pulse program and temperature
parameters are adjusted (see Notes 15 to 17).
3. The ICONNMR setup is similar to a 1D 1H NMR data collection as shown in Figure
5.
4. A standard 2D 1H-13C-HSQC experiment (Bruker hsqcetgpsisp2 pulse program) is
used to determine the 1H-13C chemical shift correlations for all

13

C-labeled

metabolites in the metabolomics sample (see Note 19).
5. Typical experimental parameters for a 2D 1H-13C-HSQC NMR spectrum obtained
on a Bruker 700 MHz spectrometer with a cryoprobe correspond to 128 scans, 32
dummy scans, and a 1.0 s relaxation delay. The spectrum is collected with 2 K data
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points and a spectrum width of 4,734 Hz in the direct dimension and 64 data points
and a spectrum width of 18,864 Hz in the indirect dimension (see Note 14).
6. Implementation of fast NMR methods that includes non-uniform sampling
significantly decreases data acquisition time and/or increases spectral resolution,
but may introduce artifacts (see Note 20).
7. Collect the 2D 1H-13C-HSQC NMR spectrum for each replicate and each group (see
Note 6).
8. The data is processed initially with Topspin to verify spectral quality, but exported
for further analysis (see Figure 2.6B).

2.3.10 Mass Spectrometry Data Collection
2.3.10.1 Direct-Injection (DI) Mass Spectrometry
1. Positive-ion direct infusion electrospray ionization mass spectrometry (DI-ESI–
MS) data are collected on a Synapt G2 HDMS quadrupole time-of-flight (TOF) MS
instrument equipped with an ESI source.
2. The mass spectrometry experiments are carried out at a flow rate of 10 μL/min for
1 min.
3. The mass spectra are acquired in positive ion and negative mode over a mass range
of m/z 50 to 1200.
4. Mass spectra are acquired for 0.5 min using the following optimized source
conditions: 2.5 kV for ESI capillary voltage, 60 V for sampling cone voltage, 4.0
V for extraction voltage, 80 °C for source temperature, 250 °C for desolvation
temperature, 500 L/h for desolvation gas, and 15 μL/min flow rate of injection
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5. Collect the DI-ESI–MS mass spectral data for each replicate and each group (see
Note 6 and Figure 2.7).

Figure 2.7: MS metabolomics data. Examples of typical (A) DI-ESI-MS spectrum, (B) typical
analysis sequence, (C) LC base peak chromatograms and (D) MS spectrum acquired from
metabolomics samples.
2.3.10.2 Liquid Chromatography - Mass Spectrometry
1. Liquid chromatography - mass spectrometry (LC–MS) data are collected on a
Waters ACQUITY M-class Xevo G2-XS QToF MS instrument equipped with an
ESI source.
2. The LC-MS mass spectrum are acquired with the following system parameters:
•

LC System: Waters ACQUITY M-class

•

Column: ACQUITY HSS T3 Column 1.0 mm x 100 mm
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•

Mobile phase A: 0.1% Formic Acid in Water

•

Mobile phase B: 0.1% Formic Acid in Acetonitrile

•

Flow rate: 70 µL/min

•

Run time: 10 min

•

Injection volume: 2 µL

•

MS system: Xevo G2-XS QtoF

•

Ionization mode: ESI + and –

•

Capillary voltage: 2.8 kV

•

Cone voltage: 30 V

•

Source temp: 120 °C

•

Desolvation temp: 500 °C

•

Cone gas flow: 18 L/h

•

Lock mass:
− Positive mode: Leukin- Enkephalin, m/z 556.2771
− Negative mode: Leukin- Enkephalin, m/z 554.2615

•

Acquisition mode: MSE

•

Acquisition range: 50 to 1200 m/z

•

Collision energy (LE): 6 eV

•

Collision energy (HE): 20 to 40 eV

3. The temperature for the LC column and auto sampler is set to 40 °C and 4 °C,
respectively.
4. Create a sample analysis sequence and inject the QC samples five times for column
conditioning. After second QC injection, monitor peak area (<25% RSD), retention
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time (+/- 0.05 min), and mass accuracy (+/- 3ppm) until the end of the fifth
injection. If the QC samples pass the minimal system performance parameters, then
acquire data. If not, do not collect data until the issue has been resolved and the QC
samples pass the minimal system performance parameters.
5. Collect the LC-MS mass spectral data for each replicate and each group (see Note
6 and Figure 2.7).

2.3.11 NMR Data Processing (see Note 21)
All NMR data is processed and analyzed with our MVAPACK software [21], our PCA/PLS-DA
utilities [22],

NMRPipe [23], and

NMRViewJ [24]. See example processing scripts at

http://bionmr.unl.edu/wiki/Scripts.

2.3.11.1 1D 1H NMR (see Figure 2.8A)
1. A 1.0-Hz exponential apodization function is applied to the FID.
2. Fourier transform the FID.
3. The resulting NMR spectrum is automatically simultaneously phased corrected and
normalized with the phase-scatter correction algorithm [45].
4. The NMR spectrum is referenced to the peak of TMSP-d4 (0.0 ppm).
5. Noise and solvent regions are manually removed.
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Figure 2.8: MVAPACK processing scripts. (A) Schematic illustration of the major processing
steps. Examples MVAPACK processing script for (B) 1D 1H NMR dataset, (C) 2D 1H-13C
HSQC dataset, and (D) combined NMR and MS datasets. The numbered steps in the flow diagram
correspond to the numbered lines in the processing scripts.

2.3.11.2 2D 1H-13C-HSQC NMR (see Figure 2.8B)
1. A sine-bell apodization function is applied to the t2 dimension.
2. The t2 dimension is zero filled three times.
3. The t2 dimension is Fourier transformed, manually phase corrected and the
imaginary data deleted.
4. The matrix is transposed.
5. A sine-bell apodization function is applied to the t1 dimension.
6. The t1 dimension is zero filled three times.
7. The t1 dimension is Fourier transformed and manually phase corrected.
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8. The NMR spectrum is referenced in both dimensions to the peak of TMSP-d4 (0.0
ppm).

2.3.12 Mass Spectrometry Data Processing - DI-ESI–MS (see Figure 2.8C)
1. Mass spectral data processing is first performed using MassLynx V4.1.
2. A background subtraction is performed on all spectra using appropriate reference
spectra, such as a free drug or toxin used to treat a cell culture. The background
subtraction of each spectrum is performed in a class-dependent manner (i.e., only the
MS reference spectrum of the drug/toxin used to treat the cell culture is used for
background subtraction). Accordingly, mass spectral signals from the drug/toxin
treatments are guaranteed to not influence subsequent analyses. An example of a typical
MS spectrum from a metabolomics sample is shown in Figure 2.7.
3. The background-subtracted mass spectra are then loaded into MVAPACK as a text file
for binning and normalization.

2.3.13 Mass Spectrometry Data Processing - LC-MS (see Figure 2.9)
All LC-MS data is processed and analyzed with Progenesis QI (version 2.0.). Please see the
Progenesis

QI

user

guide

(http://storage.nonlinear.com/webfiles/progenesis/qi/v2.2/user-

guide/Progenesis_QI_User_Guide_2_2.pdf) for detailed instructions.
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Figure 2.9: LC-MS processing protocol. The small molecule discovery workflow using the
Progenesis QI software is diagrammed. (top left) Summary of the major steps in the LC-MS
processing protocol, which also describes each figure block in order starting from middle-left to
bottom-right. Images are screenshots from the Progenesis QI software.
2.3.13.1 Data Upload
1. Go to File and create a new experiment. Select a location to store the experiment
file. Click Next.
2. Select the machine type (i.e., high resolution mass spectrometer) and the polarity
used to collect the mass spectrum (i.e., positive or negative). Click Next.
3. Select the expected adducts [e.g., M+Na+

(+), M+H+CH3OH+ (+,-),

M+H+CH3N+(+,-), M+H3O+ (+)] and click Create experiment.
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4. Go to Select your run data, choose the MS Format and click Import. Click Next.
5. Apply Lock mass calibration. Click Next.
6. Select Import.

2.3.13.2 Perform Automatic Processing
1. Click on Start automatic processing.
2. Select an alignment reference by choosing Use the most suitable run from
candidates that I select. Click Next.
3. Select all QC runs. Click Next.
4. Select Yes, automatically align my runs. Click Next. Click Next again
5. After processing is complete, click Section Complete to move forward to the Review
Alignment stage.

2.3.13.3 Review Alignment
1. Interrogate the number of vectors and alignment scores.
2. Examine the distribution of green (good alignment), yellow (acceptable alignment)
and red (needs review) alignments present in the ion intensity map.
3. As necessary, manually edit the alignments. Make sure that each ion is properly
aligned across all replicates and to the reference mass spectrum. This is
accomplished by interactively adjusting the alignment vector positions.
4. After processing is complete, click Section Complete.

2.3.13.4 Create Experiment Design

54

1. Choose the type of experiment and click Create (see Note 22).
2. Click Add condition and rename it according to the groups in the study (e.g.,
control, treated, etc.).
3. Drag and drop each replicate mass spectrum into each of the defined groups from
2.
4. After processing is complete, click Section Complete to move forward to the Peak
Picking stage.

2.3.13.5 Peak Picking
1. Click Change parameters.
2. Go to the Peak picking limits grid and define a minimum peak width to reject noise
spikes. A typical minimum peak width is 0.05 min.
3. Click Start peak picking.
4. After the process is completed, go to Review normalization and choose the
normalization method. Normalize to all metabolites is the default. A preferred
choice is to normalize to an internal standard (e.g., reserpine).
5. After processing is complete, click Section Complete to move forward to the
Deconvolution Review stage.

2.3.13.6 Review Deconvolution (see Note 23)
1. Go to the Deconvolution Review grid.
2. On the left panel, choose organize the compound features by adducts.
3. Click over an ion metabolite to review its adducts (see Note 24).
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4. To remove an adduct assigned to a metabolite, right click on the peak in the adduct
panel and click Remove from compound.
5. After the processing is complete, click Section Complete to move forward to the
Compound Statistics stage.

2.3.14 NMR Data Preprocessing for Multivariate Modeling
In order to obtain an accurate and reliable multivariate statistical model, it is essential that the data
set is properly preprocessed to remove normal systematic variations resulting from biological
variability, instrument instability, and inconsistency in sample handling and preparation. Key
preprocessing steps include: (1) alignment, (2) normalization, (3) binning, and (4) scaling, which
is illustrated in Figure 2.8. Examples of results from a variety of statistical models are shown in
Figure 2.10. All NMR datasets are processed with our MVAPACK software [21] and our
PCA/PLS-DA

utilities

[22].

http://bionmr.unl.edu/wiki/Scripts.

See

example

MVAPACK

scripts

at
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Figure 2.10: Univarate and multivariate statistical models. Example of PCA scores plot and the
associated metabolomics tree diagram for (A,D) 1D 1H NMR dataset, (B,E) DI-ESI-MS dataset,
and (C,F) combined 1D 1H NMR DI-ESI-MS dataset. (G) NMR and (H) MS back-scaled loadings
from an OPLS model generated from combined 1D 1H NMR DI-ESI-MS dataset. Reproduced
with permission from [61]. (I,J) PCA scores plot and OPLS back-scaled loadings generated from
2D 1H-13C HSQC NMR data set. Reproduced with permission from [1]. (K) Example heat-map
with hierarchal clustering summarizing specific metabolite changes per replicate and the relative
clustering of each individual replicate. Reproduced with permission from [L]. Example metabolic
pathway summarizing the major metabolite changes between the two groups. Reproduced with
permission from [1].
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2.3.14.1 1D 1H NMR
1. Spectra may first be normalized based on either the total cell count or the total
protein concentration using the BCA (Biscinchronic Acid) protein estimation assay
using parallel dishes treated similarly on the same day.
2. Spectra are normalized with the PSC algorithm [46].
3. Spectra are aligned and/or binned. For principal component analysis (PCA),use the
following parameters:
•

The spectral data are globally aligned to the peak of TMSP-d4 at 0.0 ppm.

•

The spectral data are regionally aligned using the icoshift algorithm [47].

•

The spectral data are binned using the adaptive, intelligent binning
algorithm [48].

For orthogonal projection to latent structures (OPLS), use the following
parameters:
•

The spectral data are globally aligned to the peak of TMSP-d4 at 0.0 ppm.

•

The spectral data are regionally aligned using the icoshift algorithm [47].

•

The spectral data is not binned. Instead, the full-resolution spectral data is
used to build the model.

4. Solvent peaks and noise regions are manually removed.
5. The data set is scaled using Pareto scaling.
6. A PCA or OPLS model is generated from the data matrix.

2.3.14.2 2D 1H-13C-HSQC NMR
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1. Spectra may first be normalized based on either the total cell count or the total
protein concentration as explained above.
2. The spectral data is normalized using standard normal variate normalization.
3. The spectral data is binned using a generalized adaptive, intelligent
binning algorithm [48].
4. The data are Pareto-scaled.
5. A PCA or OPLS model is generated from the data matrix.

2.3.15 Mass Spectrometry Data Preprocessing for Multivariate Modeling
LC-MS datasets need to be preprocessed in a similar manner to NMR spectra. The LC-MS datasets
are processed with Progenesis QI (version 2.0.).

2.3.15.1 DI-ESI–MS
1. All mass spectra are linearly re-interpolated onto a common axis that spanned from
m/z 50 to 1,200 in 0.003 m/z steps, resulting in 383,334 variables prior to
processing.
2. The mass range m/z 1,100 to 1,200 is removed prior to binning because of the low
probability of observing a metabolite in this region.
3. The mass spectra are uniformly binned using a bin width of 0.5 m/z, resulting in a
data matrix of 2,095 variables.
4. The MS data matrix is normalized using probabilistic quotient (PQ) normalization.
5. The MS data matrix is then scaled to unit variance prior to modeling.
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6. A PCA or OPLS model is generated from the data matrix.

2.3.15.2 LC-MS (see Note 25 and Figure 9)
1. The LC-MS datasets are processed with Progenesis QI (version 2.0.). Please see the
Progenesis

QI

user

guide

(http://storage.nonlinear.com/webfiles/progenesis/qi/v2.2/userguide/Progenesis_QI_User_Guide_2_2.pdf) for detailed instructions.
2. Right click on the Compounds table and select Quick Tags.
3. Set the ANOVA cutoff value to 0.05.
4. Click Create tag.
5. All metabolites with an ANOVA p-value ≤ 0.05 will be marked with a red tag.
6. Repeat the process to create a tag for fold change (see Note 29). Right click on the
Compounds table and select Quick Tags
7. Set the fold change cutoff value to 2.
8. All metabolites with a fold change greater than 2 will be marked with a green tag.
9. Create a filter to show only tagged metabolites. Click Create on Filter grid to open
the filter dialog box.
10. Select the tags and then drag to the box Show compounds that have all these tags.
Click OK.
11. Only the metabolites that match the criteria are showed and will be used for
metabolite identification.
12. Go to the Compound statistics grid. The statistical analysis is available as a PCA
scores plot. A statistically relevant dataset is indicated by replicate samples
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clustering together in the scores plot. Furthermore, the set of control and treated
replicates form distinct clusters from each other.
13. Go to File and select export all measurements. A comma-separated value (csv) file
will be created with a list of several values per metabolite: (1) metabolite
identification, (2) m/z value, (3) charge, (4) retention time, (5) relative abundance,
(6) ANOVA value and other parameters.

2.3.16 Statistical Analysis (see Figure 10)
Data sets are analyzed with our MVAPACK software [21], our PCA/PLS-DA utilities [22], and R
[49]. See example MVAPACK and R scripts at http://bionmr.unl.edu/wiki/Scripts.

A major challenge in the analysis of metabolomics datasets, and a common source of error, is the
incorrect application of statistics. This results from a number of prevailing misconceptions within
the metabolomics community. For example, a multivariate model, especially supervised methods
such as PLS or OPLS, needs to be properly validated. Validation can be accomplished with CVANOVA [50] and/or response permutation testing [51]. Conversely, the resulting R2 and Q2 values
only provides a measure of the model fit to the original data and an internal measure of consistency
between the original and cross-validation predicted data, respectfully. R2 and Q2 values do not
provide for model validation without a proper standard of comparison.

PCA, PLS, and OPLS are routinely used to model metabolomics data. Nevertheless, there are
misconceptions regarding the proper application and interpretation of the resulting models,
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especially in regards to comparing PCA, PLS, and OPLS models. For example, PCA finds the
largest source of variance in the dataset irrespective of the intent of the study. So, an observed
separation between treated and untreated groups in a PCA scores plot may have nothing to do with
the treatment if some other larger variant is present in the dataset. Supervised methods, like PLS
and OPLS, address this issue by aggressively forcing group separation based on the defined group
membership. Hence, PLS and OPLS models almost always yield separated groups, as by design!
As a result, PLS and OPLS models are easily over-fitted, especially for metabolomics data sets
since the number of variables (e.g., metabolites) are typically larger than the number of replicates.
Again, model validation is essential for PLS and OPLS.

Another serious misconception is the false belief that PLS/OPLS is a better method than PCA and
may find group differences when PCA fails to expose group separation. Instead, PCA, PLS and
OPLS are simply different models that extract different information and achieve different goals.
Thus, if PCA fails to identify group separation it is unlikely that PLS/OPLS will yield a valid
model [51]. Remember, PCA finds the largest source of variance. If PCA doesn’t find any major
variance, then there cannot be any smaller group-specific variance.

PLS and OPLS appear to provide similar models. In fact, a comparison of PLS and OPLS scores
plots generated from the same data set may suggest the only difference is a relative rotation of the
group-defined ellipses. Nevertheless, this apparently subtle change highlights a critical difference.
Simply, OPLS places group-independent variance (e.g., confounding factors such as differences
in diet, age, race, etc.) orthogonal to group-dependent variance. Conversely, PLS entangles both
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group-independent and group dependent variance. In this regards, a metabolite identified as a
major contributor to an OPLS model is strictly the result of the defined group difference. For PLS,
metabolite changes may be a result of the group difference, a confounding factor or a combination
of both. Accordingly, a PLS identified metabolite may be of little interest to the intent of the study.
In this regard, we strongly recommend always using OPLS instead of PLS.

2.3.16.1 Univariate Analysis
1. Relative metabolite abundances are inferred from NMR and/or mass spectral peak
heights and/or peak volumes.
2. Relative metabolite abundances are then normalized on a per spectrum basis. One
common approach is to convert the absolute peak intensities (arbitrary units) to a
Z-score:
𝑍=

𝐼𝑖 −𝐼 ̅
𝜎

(1)

where 𝐼 ̅ is the average peak intensity for the spectrum, Ii is the intensity of peak i,
and 𝜎 is the standard deviation of peak intensities. Peak intensities may also be
normalized to the total number of cells, to the total protein concentration (see
section 2.3.14.1), to the average spectral noise, or to an internal standard (see Note
26). Relative metabolite abundances may also be converted to fold-changes:
𝐼

𝐹 = 𝐼𝑖

𝑜

(2)
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where Ii is the normalized peak intensity of metabolite i from a treated spectrum
and Io is the normalized peak intensity of metabolite i from the control or untreated
spectrum.
3. A standard Student’s t-test is commonly used to determine statistical significance
only for a pairwise comparison of metabolite changes based on either fold-changes
or normalized peak intensities (see Note 27). A statistically significant difference
is typically identified by a p-value < 0.05.
4. A Student’s t-test is insufficient for the multiple comparisons that are common to a
metabolomics study [51, 52]. In order to identify the set of metabolites that exhibit
a statistically significant change, a multiple hypothesis test correction method such
as a Benjamini-Hochberg [53] or a Bonferroni [54] correction must be applied (see
Note 28).
5. A heat-map with hierarchical clustering (see Figure 2.10k) is commonly generated
from the fold-changes or normalized peak intensities using R (see example R script
at bionmr.unl.edu/wiki/scripts). The heat-map may contain relative metabolite
abundances for each individual replicate in the study or simply the replicateaverages for each group (see Note 29).

2.3.16.2 Multivariate Analysis
1. Generate a PCA and or OPLS model from the data matrix.
2. Fractions of explained variation (R2X and R2Y) are computed during PCA or OPLS
model training.
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3. The PCA or OPLS model is internally cross-validated using seven-fold Monte
Carlo cross-validation [55] to compute Q2 values (see Note 30).
4. For an OPLS model, the Q2 value is compared against a distribution of null model
Q2 values in 1000 rounds of response permutation testing [51]. Group membership
is randomly reassigned to generate the set of null models. A p-value is calculated
from a comparison of the true Q2 value to the set of null model Q2 values (see Note
31).
5. The model is further validated using CV-ANOVA significance testing, which is
used to calculate another model p-value [50] (see Note 31).
6. Scores plots (see Figure 2.10a,b,c,i), back-scaled loadings plots (see Figure
2.10g,h,j), S-plots and/or SUS-plots are often generated from OPLS models.
7.

PCA/PLS-DA utilities [22] is used to define group membership by drawing an
ellipse per group onto the scores plots (see Figure 2.10a,b,c,i). Each ellipse
corresponds to 95% confidence interval for a normal distribution. The PCA/PLSDA utilities also generates a metabolomics tree diagram that identifies the statistical
significance (p-value and/or bootstrap value) and the relative similarity of each
group in the scores plot (see Figure 2.10d,e,f). The p-value or bootstrap number
from the pairwise comparison is labeled at each node in the tree.

2.3.17 Data Analysis - Metabolite Assignment from 1D 1H NMR Data
All NMR data is analyzed with NMRPipe [23], NMRViewJ [24], and Chenomx. See example
scripts at http://bionmr.unl.edu/wiki/Scripts.
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1. The identification of metabolites in a 1D 1H NMR spectrum is performed with software
programs such as Chenomx. Chenomx matches the experimental 1D 1H NMR spectrum
to a database of 1D 1H NMR spectra of known metabolites. Chenomx attempts to
explain or describe the experimental NMR spectrum by combining or summing as
many of the individual reference metabolite NMR spectra as needed. In addition to
metabolite identification, Chenomx also provides an estimate of the metabolite
concentration (see Note 32).
2. Upload the 1D 1H NMR spectrum for processing. The NMR spectra can be batch
processed or processed one at a time.
3. The 1D 1H NMR spectrum is phased.
4. The 1D 1H NMR spectrum is calibrated and reference to TMSP-d4, using the known
concentration of TMSP-d4.
5. The properly phased and calibrated 1D 1H NMR spectrum is then sent to the Chenomx
profiler where the spectrum is compared against the metabolite library.
6. Chenomx will overlay a 1D 1H NMR reference spectrum for each metabolite identified
in the experimental 1D 1H NMR spectrum. The spectral overlay needs to be manually
adjusted to optimize the alignment of the experimental 1D 1H NMR spectrum with the
reference spectrum. Figure 2.6A shows an example of a labeled 1D 1H NMR spectrum.
7.
2.3.18 Data Analysis - Metabolite Assignment from 2D 1H-13C-HSQC NMR Data
All NMR data is analyzed with NMRPipe [23], NMRViewJ [24], and Chenomx. See example
scripts at http://bionmr.unl.edu/wiki/Scripts.
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2.3.12.1 NMRPipe Processing to Obtain .ft2 and .nv Files.
1. The data files from ICONNMR can be used directly by NMRPipe to process the
2D 1H-13C-HSQC spectra.
2. On a Linux workstation, open a terminal and go to the directory that contains the
NMR data. Type bruker to start the NMRpipe software.
3. Read in the experimental parameters file by clicking Read Parameters and verify
that all of the parameters have been correctly updated. Confirm that the mode of
data collection has been set to echo-antiecho if the NMR spectrum was collected
with the hsqcetgpsisp2 pulse program.
4. Click Update Script to save an NMRPipe processing script fid.com file in the
working directory.
5. Type ./fid.com to start the NMRPipe processing script.
6. When the NMRPipe processing has finished, type nmrDraw to view the processed
NMR

spectrum.

Please

see

the

NMRPipe

and

nmrDraw

tutorial

(https://spin.niddk.nih.gov/NMRPipe/doc1/) for detailed instructions.
7. Phase the NMR spectrum in NMRpipe and note the p0 and p1 values for both the
1

H and 13C dimensions.

8. Edit the NMRPipe processing script hsqcproc.com and replace the parameters
associated with the NMRPipe phase correction command, ps, with the p0 and p1
values obtained from step 7.
9. Type ./hsqcproc.com to start the NMRPipe processing script
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10. Repeat steps 3 to 9 for each 2D 1H-13C-HSQC NMR spectrum in the dataset. This
produces a set .ft2 files. One .ft2 file is created for each 2D 1H-13C-HSQC NMR
spectrum collected for each replicate from each group.
11. Copy all of the .ft2 files into a new folder and use the NMRPipe script addnmr.com
to generate NMRviewJ files from the .ft2 files. A .nv file will be generated for each
individual spectrum (.ft2 file) with an numerically incremented root name of
“Final_”. In addition, the script will combine all of the NMR spectra together into
a single file called results.nv. The script will also generate the text file, rate.txt, that
lists all of the individual .nv files (Final_).

2.3.18.2 Peak Picking and Peak Integration of 2D

1H-13C-HSQC

Spectra in

NMRviewJ.
1. Type nmrviewj to start NMRviewJ. Please refer to NMRViewJ documentation
(http://docs.nmrfx.org/) for more details.
2. From the Dataset toolbar in the main window, use the Open and Draw Datasets
function to select the result.nv file.
3. Right click and select attributes to open the attributes window.
4. In the attributes window, select the PeakPick tab.
5. In the blank Lists field in the attribute window, type a filename (i.e., lists) for the
new peak pick list. Click the Pick button. The software will automatically peak pick
the displayed spectrum and populate lists with the peak ID number, chemical shifts,
and intensity.
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6. Choose Show Peak Table from the Peak toolbar on the main window. A peak table
window will open that lists the peak ID, peak intensity and the peak chemical shifts.
7. Manually edit the peak list and remove solvent peaks, noise peaks or other spectral
artefacts. Peaks are deleted from the peak table by using the delete function in the
PeakPick tab in the attributes window along with the spectrum display window. In
the spectrum display window, use the mouse to position the two cursors around any
peak or spectral region to form a box. Then, click the Delete button under the
PeakPick tab in the attributes window to remove the peak(s).
8. After the peak table has been completely edited, on the peak table window choose
the Edit tab and select Compress & Degap. Answer yes to the pop-up question. This
will finalize changes to the peak list and prevent any further edits.
9. On the peak table window choose the Edit tab and then select Save Table. A file
browser window will open in order to choose a name and location to save the new
peak list file. The saved peak pick file can be viewed and edited by Excel.
10. In order to obtain peak intensities across the entire set of NMR spectra in the
dataset, click on the Analysis tab on the main window and select Rate Analysis. A
set-up window for the Rate Analysis will open.
11. In the Rate Analysis set-up window:
•

set the Prefix for matrix numbers field to Final_

•

set the Peaklist field to lists (defined in section 2.3.18.2 step 5).

•

make sure Auto fit is checked.

•

use all other default settings.

•

Click Load time file.
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•

In the file browser window, select rate.txt (created in section 2.3.18.1 step 11).

•

Click Measure All. The software automatically populates the table in the Rate
Analysis set-up window with all of the peak intensities across the entire NMR
dataset.

•

Click Save Table. In the file browser window, save the peak intensities table to
a new filename (i.e., intensities).

12. The peak list (i.e., list) and the peak intensities (i.e., intensities) files are merged in
Microsoft Excel using the common peak ID column. The ppm1 (1H ppm) and ppm2
(13C ppm) columns are added to the peak intensities columns to generate a complete
matrix of NMR peaks and intensities across the entire data set.
13. The merged Excel file is saved to a new filename.
2.3.18.3 Metabolite Assignments from 2D 1H-13C-HSQC Peak Lists
1. The complete list of peaks obtained from the NMRviewJ analyses is searched using
NMR metabolomics databases such as HMDB [28], BMRB [29], or other databases
(see Note 33).
2.

On the HMDB homepage, choose the Search tab and select 2D NMR Search.

3. From the Spectra Library pull-down menu, choose 13C HSQC.
4. Cut and paste the 2D 1H-13C-HSQC peak lists into the Peak List field. One set of
1

H and 13C chemical shifts, respectively, per line. Chemical shift values should only

be separated by white space.
5. Set the 1H chemical shift error tolerance to 0.05 ppm (X-axis Peak Tolerance ±
field) and the 13C chemical shift error tolerance to 0.10 ppm (Y-axis Peak Tolerance
± field).
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6. Click the Search button. Depending on the size of the peak list, the software will
return a ranked-order list of possible metabolites based on the number of chemical
shift matches to reference spectrum.
7. Manually curate the list of potential metabolite assignments based on the number
of chemical shift assignments, the quality of the spectral overlap (i.e., chemical shift
match), number of other metabolites in the same metabolic pathway, and the
biological system (i.e., is it a reasonable or possible metabolite for the organism),
8. Obtain additional NMR (e.g., HMBC, HSQC-TOCSY) and/or MS spectral data to
confirm or refute the assignment.
9. An assigned 2D 1H-13C-HSQC spectrum is shown in Figure 2.6B.

2.3.19 Data Analysis - Metabolite Assignments from LC-MS Data
The identification process is accomplished using the Progenesis QI (version 2.0.) software (see
Note 34 and Figure 2.9). Please see the Progenesis QI user guide for detailed instructions
(http://storage.nonlinear.com/webfiles/progenesis/qi/v2.2/userguide/Progenesis_QI_User_Guide_2_2.pdf).

3.19.1 Identification of Compounds (see Note 36)
1. Make sure the filter created in section 2.3.15.2 step 9 is applied and then proceed
to Identity Compounds grid.
2. At the left panel, define the method to be used. In this case, select Progenesis
MetaScope.
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3. Choose the search parameter, in this case choose HMDB (see Note 35).
4. Click Search for identifications.
5. After few min, a dialogue box will open identifying the number of metabolites
identified. Click ok to close.
6. All ions with possible identifications will presented as a solid gray icon on the left
side.

2.3.19.2 Incorporation of Theoretical Fragmentation (see Note 36).
1. On the left panel, select ChemSpider [27] as the identification method (see Note
37).
2. In the Choose search parameter field, choose default and then click edit.
3. Set the following parameters:
•

Select name as theoretical fragmentation.

•

Set precursor tolerance to 5 ppm.

•

Tick Perform theoretical fragmentation box.

•

Set the Fragment tolerance to 5 ppm.

4. Click Save.
5. Click Search for identifications.
6. After a few minutes, a dialogue box will open displaying the number of metabolites
identified. Click ok to close.

2.3.19.3 Accepting Compounds Assignment
1. Proceed to Review Compounds grid.
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2. Go to the option Choose the correct identification and set a threshold of 45. The
choice of a threshold is empirical and may need refinement based on the specific
properties of the dataset. The higher the threshold setting, the more confident are
the assignments, but the more restrictive analysis may result in a lower number of
assignments.
3. Click Accept identifications. All identifications with a score of 45 or above will be
accepted automatically.

2.3.19.4 Review and Accept the Identifications Manually (see Note 38)
1. Select a metabolite from the list.
2. Go to the Possible identifications grid.
3. In the bottom panel, select the desired identification threshold for the metabolite.
2.4. Notes
1. Isotopically-labeled reagents commonly used for NMR are not radioactive and do not
require special handling or safety precautions. However, gloves and eye protection are
standard safety protocol for preparing all types of metabolomics samples.
2. Deuterated solvents, such as D2O or DMSO, are very hygroscopic and require storage in a
drybox and need to remain sealed until used.
3. The pH of a 100% D2O sample using a standard pH probe may not report the correct pH.
A standardly applied correction is: pD = pH + 0.4. Conversely, a recent study by K. A.
Rubinson [56] suggests the variance is not as significant, especially for a phosphate buffer,
and a correction may not be required.
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4. Complete cell survivability in each group is essential to a successful metabolomics study.
This may be particularly challenging in a study that involves treating cells with a drug,
toxin or some other condition (including nutrient depletion or supplementation) that is
expected to alter cell viability. Thus, the goal is to identify a dosage and time for the
experimental paradigm that will stress the cells, prior to the induction of cell death. In this
regard, the observed metabolomic changes will be a result of the cell’s immediate response
to the mechanism of action of the experimental condition, or the adaptation of the cell to
the stress, and not a general cell death response. We typically identify the dosage by
collecting a series of growth curves over a range of drug/toxin concentrations and compare
them to a growth-curve from untreated cell culture.
5. The resulting composition of the metabolome is easily perturbed by any difference in the
protocol. Thus, it is essential that every sample is handled in exactly the same manner as
reasonably as possible. Bias can be induced if cells are cultured in different incubators or
shakers, if cells are handled by different personnel, if cells are treated with a different wash,
buffer or media (even if it is the exact same recipe as prepared by the same individual), or
if the time to process the cells differ, etc. In essence, any source of variance (regardless of
how slight) may lead to a significant biologically-irrelevant change in the metabolome. As
a result, an important aspect of the protocol is to randomize the processing of each sample
to minimize any bias induced by sample order. The order of sample processing should
change at each step of the protocol. It is especially critical to randomly interleave replicate
samples from each group.
6. Randomization of samples throughout the protocol is essential to avoid the introduction of
bias. For example, if all of the control samples are processed together and first, and all of
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the treated samples are processed second, a difference between the controls and treated
samples may be due to the processing order instead of the expected response to treatment.
Consider another example consisting of a set of twenty samples numbered 1 to 20. If the
samples are always processed in the order of the sample number, then a time-bias will be
induced across the entire dataset. Sample 20 will always be processed after a maximal waittime and sample 1 will always be processed the quickest. Accordingly, biologicallyrelevant differences in the metabolomes will accumulate between the samples due to the
difference in processing time. Instead, if the order is constantly changed at each step, the
processing time and any impact on the metabolome will be randomized, which in turn will
minimize or eliminate any bias.
7. The number of replicates per group will have a significant impact on the quality of the
study and the statistical validity of the outcomes. In general, it is best to maximize the
number of replicates per group, within reason, with a typical target of ten replicates per
group. A variety of experimental considerations may impact the number of replicates that
are practical for a given study. For example, a large number of groups may require a
reduction in the number of replicates per group. Another consideration is the impact of the
number of replicates on the quality of the metabolomics samples. Sacrificing quality for a
greater number of replicates will not likely lead to a successful outcome. Conversely, a
limited number of replicates < 4 per group will likely provide meaningless results.
8. Other studies have used a combination of isotopically labeled and non-labeled carbon
sources. The conditions of optimal labeling should be standardized for every cell line/type
used for experimentation considering the composition/recipe of the culture media and the
required carbon sources (glucose, pyruvate or glutamine) for cell growth. A time course
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between 1-48 h should be performed to assess the rate of carbon consumption. Examples
of media used for

13

C-carbon labeled metabolomics are Dulbecco's Modified Eagle

Medium DMEM (11966-025, 10938-025, 11960-044 and A14430-01) and RPMI
(11879020) from GIBCO/Life Technologies
9. Removal of proteins and other biomolecules by methanol or ethanol precipitation is
preferred over mechanical filtration methods or the application of Carr–Purcell–Meiboom–
Gill (CPMG) NMR T2 filtering techniques. Filtering techniques may remove metabolites
that bind to biomolecules leading to biologically-irrelevant group differences [111].
10. Smaller diameter NMR tubes of 3 mm (160 μL) or 1.7 mm (35 μL) may be needed if the
available metabolomics sample is limited. Filling of these smaller diameter NMR tubes
may require a liquid handling robot, such as a Gilson 215 Liquid Handler. In addition, the
NMR acquisition parameters will likely need to be adjusted to account for the lower
sensitivity due to the lower number of nuclei in the samples.
11. Topshim requires the sample contains either a D2O or H2O solvent. It is advisable to create
a shim file with a parameter set that produces an optimal set of shims for your sample type.
Read in a shim file using the Bruker command rsh and select the appropriate Topshim shim
file. If you are doing this for the first time, complete the command topshim, if you are not
satisfied with the shim performance use command topshim tuneb tunea to obtain an
improved set of shims. Write the shim set parameters with the Bruker command wsh and
save it to a new file name for future reference.
12. The 90 degree pulse length is commonly measured by incrementing the P1 pulse in the zg
pulse program by 1 μs or smaller increments; and by plotting the relative peak heights or
intensities. A maximum peak height should be observed at the pulse length corresponding
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to the 90-degree pulse. Conversely, a minimum or null spectrum should be observed at the
pulse length corresponding to the 360-degree pulse length. In practice, a more accurate
measure of the 90-degree pulse is obtained by measuring the 360-degree pulse length and
dividing by four to obtain the 90-degree pulse length. A typical 90-degree pulse length for
a metabolomics sample ranges from approximately 8 μs to 13 μs or longer. Among other
factors, the relative salt concentration of the metabolomics sample affects the 90-degree
pulse, in which a higher salt concentration results in a longer 90-degree pulse. Other factors
also contributed to the observed 90-degree pulse, so it is always necessary to
experimentally determine the 90-degree pulse for each sample or set of samples.
13. Excitation Sculpting parameters (zgesgp) - 32768 data points (TD), SW = 12.02 ppm, O1P
(transmitter offset) = 4.70 ppm, D1= 1 second, NS (number of scans) = 128, DS
(dummy/steady state scans) = 16, P1 = 9.5 -13.5 us, SPNAM (shaped pulse for water
suppression) = SINC1.1000 at 26.39 dB or 0.00228 W.
14. The NMR data acquisition parameters need to be adjusted to compensate for differences in
the field strength and sensitivity of the NMR spectrometer actually used for the data
collection. Specifically, the number of scans, the number of data points, the sweep-width
(13.79 ppm, 1H frequency range) and the frequency-offset (centered on water peak at 4.70
ppm) need to be adjusted according to the type and configuration of the NMR spectrometer
used for the study.
15. For high throughput NMR data collection please refer to the Bruker ICONNMR manual to
explore various configuration options. For example, composite experiments allow for the
collection of multiple 1D and 2D experiments for the same metabolomics sample. An
experimental set consisting of a 1D 1H, a 2D 1H-13C HSQC, and 2D 1H-13C HMBC
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experiment may be subsequently collected for the same sample before moving to the next
sample in queue.
16. It is imperative that NMR data is collected at the same temperature for a queue of
metabolomics samples. ICONNMR assists this by allowing for a temperature delay when
a large number of samples are in the SampleJet queue. For example, a 15 to 60 second
delay may be inserted prior to data acquisition to allow each sample to equilibrate to the
probe temperature. We recommend a 60 second delay for both pre- and post- sample
insertion to prevent any temperature variation.
17. Parameters to check before you queue experiments in ICONNMR for 1D 1H NMR are:
number of scans ns, number of dummy scans ds, 90 degree pulse p1, delay d1, sweep width
sw, receiver gain rg, experiment temperature te, and automation setup aunm. We
recommend using au_zgonly as the automation setup. This will collect all samples at the
same receiver gain, which will avoid peak intensity variation across the dataset.
18. In addition to 2D 1H-13C-HSQC NMR experiments, NMR metabolomics studies may make
use of HMBC, TOCSY, HSQC-TOCSY, 2D J-Resolved spectra, or other experiments.
Similarly, 15N, 31P and other isotope-labeled metabolites may be detected in addition to 1Hand

13

C-labeled metabolites. Accordingly, experimental parameters, data processing and

preprocessing methods, and data analysis techniques all need to be adjusted to
accommodate the specifics of each NMR experiment. Nevertheless, there is enough
similarity that the detail discussion of the application of 2D 1H-13C-HSQC NMR
experiments may provide a useful initial guide to the application of other NMR
experiments to metabolomics.
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19. 2D 1H-13C-HSQC parameters (hsqcetgpsisp2) - 1024 data point in F2 and F1, NonUniform Sampling at 25%, O1P = 4.7 ppm, O2P (offset for 13C) = 75 ppm, NS = 64, DS =
16, d1 =2, P1 = 10 - 13 μs depending on salinity, CPDPRG2 = garp (decoupling program),
PCPD2 = 55 us at PLW12 = 4.09 W.
20. Non-uniform sampling of 2D 1H

13

C HSQC data can be performed on metabolomics

samples. We have successfully acquired data at 20% sparsity using a burst augmented
scheduler available from http://bionmr.unl.edu/dgs-gensched.php [30]. Download the
sampling schedules as a text file for Topspin.
21. A minimalistic approach to the processing of NMR and mass spectrometry data is optimal
for a metabolomics analysis utilizing multivariate statistics such as PCA and OPLS. The
resulting multivariate statistical model is dependent on the choice of processing and
preprocessing protocols. In effect, a different statistical model is likely to be obtain based
on the presence (or absence) of baseline correction and the type of baseline correction
method chosen. Similarly, the type of weighting (apodization) function, the type of spectral
alignment or referencing, the resulting phase correction or phase correction algorithm, the
number of zero-fills or the application of linear-prediction, or any other data manipulation
method will affect the outcome of the statistical model. Accordingly, it is best to avoid any
unnecessary data processing steps since it is difficult to ascertain if the data processing
induced a biologically-irrelevant bias to the data or actually improved the model.
22. Before proceeding to statistical analysis it is necessary to create an experiment design.
Progenesis QI supports Between-subject design and Within-subject design. Betweensubject design separates samples according to the experimental condition (control vs
treated) for the statistical comparison. Within-subject design is a repeated-measures study
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design where the same subject (i.e., cell, animal, or human) is compared across the full
range of experimental conditions (before treatment and after treatment; different time
points, etc.).
23. The ions and adducts for a compound are automatically recombined by Progenesis QI, but
it is advisable to review the deconvolution results. It is important to make sure the same
pattern of adducts are assigned equally across all replicates and between all groups.
Progenesis compares each detected ion with each of its co-eluting ions. If by the chance,
their mass difference matches the difference between two adduct masses (i.e., from the
previously chosen list), then it is probably an adducted form of the same compound.
Progenesis groups the two ions as the same compound and automatically assigns the ions
to the respective adduct. However, if an interesting compound is identified in the sample,
it is important to review the deconvolution process to make sure all of the ions grouped
together are actually adducts of the same compound.
24. Adducts assigned to a compound should have the same retention time as the compound.
Thus, compare the chromatograms from the potential adduct with the compound to
determine how well the chromatograms overlay. If a poor match is observed, then remove
the adduct.
25. A primary goal of the LC-MS data analysis is to identify metabolites that exhibit significant
concentration differences between groups. This is accomplished in the Progenesis software
by creating tags to identify metabolites that exhibit a statistically significant (ANOVA
[110] p-value < 0.05) difference in relative abundance between the groups. Progenesis
relies on PCA for this analysis.
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26. For NMR, relative peak intensities are averaged across all replicates per group and also for
each NMR peak assigned to the metabolite. Most metabolites will have more than one peak
in an NMR spectrum and all NMR peaks should be incorporated into an average relative
peak intensity. Please note, NMR peaks may need to be scaled by the number of attached
hydrogens, since peak intensity is proportional to the number of nuclei.
27. Of course, there are a variety of options beyond the standard Student’s t-test such as:
Mann–Whitney U test [57], Welch's t-test [58], Hotelling's t-squared statistic [59], and oneway analysis of variance [51], among others. The proper choice of a statistical test depends
on a number of factors, which is well-beyond the scope of this protocol review. For an
introduction to the topic, please see A Biologist's Guide To Statistical Thinking And
Analysis [60].
28. In effect, the uncertainty in each pairwise comparison (as determined by the Student’s ttest) is compounded with the addition of each metabolite to a set. The actually p value for
a set of metabolites is defined as:
p = 1-(1-𝛼)m

(3)

where m is the number of hypotheses (metabolites) and 𝛼 is typically defined as 0.05.
Accordingly, a set of 10 metabolites becomes an insignificant p = 0.401 even though each
individual metabolite is statistically significant based on a pairwise Student’s t-test with a
p < 0.05.
29. A heat-map displaying all of the replicates from each group is preferred to only a groupaverage plot. Specifically, the hierarchical clustering of each replicate is indicative of the
relative group separation and provides further confirmation of an observed group
separation from a PCA, PLS or OPLS scores plot.
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30. A valid PCA, PLS or OPLS model typically has R2 values > Q2 values, and Q2 values >
0.4.
31. While p-values < 0.05 are typically acceptable, more often than not, high quality
PLS/OPLS models from metabolomics data sets yield p-values << 0.001.
32. Chenomx maintains a series of 1D 1H NMR databases for a variety of NMR field strengths
and sample pH. Use the database that matches the experimental conditions of the dataset
being analyzed.
33. Most NMR metabolomics databases function in a similar manner to HMDB [28]. Simply
upload a peak list with a set of chemical shift tolerances and obtain a list of potential
matches.
34. The identification process is also available in open source software such as Mzmine [25]
or web based tools such as MetaboAnalyst [26].
35. It is also possible to create or select your own search parameter. Click on Edit and select
Create New. Select a database file in Structure Data Format (SDF) as input.
36. The possible compound assignments are based on an overall score determined by the mass
error, retention time error, isotope similarity, fragmentation score and, if available, the
collision cross section. The confidence of the identification may be increased by including
theoretical fragmentation (see Note 37).
37. ChemSpider is a database comprised of 67 million compounds, and accordingly, is not
restricted to known metabolites [27]. But, Progenesis can use the ChemSpider database for
in silico prediction of fragmentation patterns. Progenesis cannot do this with HMDB [28].
38. Section 2.3.18.3 sets a global threshold setting for all metabolites. Sometimes this may be
too restrictive for specific metabolites, where a lower global threshold setting may cause a
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large number of erroneous assignments. Section 2.3.18.4 describes a manual approach to
adjust the threshold settings for individual metabolites to recover incorrectly missed
assignments while avoiding a high false assignment rate.
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CHAPTER 3
3. Arsenic and Neurodevelopmental Disorders
3.1 Heavy Metal and Arsenic Toxicity, an Environmental Danger
Heavy metals are naturally occurring elements with high atomic weights and densities five times
heavier than water. They are typically metals and metalloids such as mercury, lead, chromium,
and arsenic [1]. Industrial wastewater and emissions often lead to accumulation of heavy metals
in soil [2]. In addition to environmental exposure, use of products containing heavy medals lead
to human exposure. Pesticides and fertilizers often contain trace levels of heavy metals including
iron, cadmium, and cobalt [3]. Consumer products such as cosmetics may contain trace levels of
heavy metals including iron and chromium, which may be absorbed through the skin [4]. Heavy
metals are highly toxic, and many are known carcinogens. The threat level posed by a given heavy
metal is highly dependent on the level and nature of the exposure.
One of the higher risk heavy metals to humans is arsenic. Arsenic is a common metalloid typically
exposed to humans through contaminated water supplies [5]. Production of tube wells in
Bangladesh with arsenic contamination put between 35 to 77 million people at risk [6]. This
contaminated water may even be used to water crops, resulting in arsenic build up in the food
supply. In south east Asia, arsenic contaminated wells led to arsenic build up in rice [7]. In the
United States, arsenic exposure is typically through food and water. Roughly 2.1 million
Americans use water that contains 10 μg/L of arsenic [8].
Arsenic is a known carcinogen, and has been associated with skin, lung, and bladder cancer [9].
Unlike other cancers, epideological studies rather than animal models were used to establish a
dose-response relation. Specifically, wells in Taiwan with high levels of arsenic were used to
establish cancer rates [10]. After establishing arsenic as a carcinogen, the exposure limit was
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lowered to 10 μg/L from 50 μg/L [11]. However, the risks of lower levels of exposure are difficult
to measure.
Neurological disorders are often associated with low levels of exposure often through water and
food. Neurological symptoms are typically observed in children or pregnant women. Studies have
linked high levels of arsenic exposure to hindered learning development. A study on school
children observed arsenic levels in urine at 50 μg/L was corrolated with lower scores in language
and memory tests [12]. Another study measured arsenic in the blood of children. Children found
with arsenic levels of 147 μg/L scored lower in cognative behavior tests [13]. Children exposed
through arsenic in drinking water at levels of 106 to 142 mg/L had lower IQ scores [14].
Nevertheless, these studies have raised concerns and suggest arsenic exposures levels, particularly
for products intended to be used by children and pregnant women, should be reevaluated.
Establishing a lower limit of arsenic exposure is difficult since epidemiological studies have not
yielded consistant results [15]. Additionally, epidemiological studies do not provide a doseresponse relationship between arsenic exposure and neurological effects. Further complicating the
situation is the fact that other nutritional defects, or additional neurotoxins may contribute to the
neurological disorders attributed to arsenic [16]. Recently, the FDA proposed a standard of 10
ppb of arsenic in apple juice; however, more research is needed before a safe level of exposure can
be determined [17].

3.2 Metal Xenobiotics and Metabolism
While Epidemiological data is not sufficient to establish a safe limit, understanding the mechanism
of toxicity may provide more insights in how arsenic disrupts neurological functions. The toxic
effect of arsenic is highly dependent on the dosage and route of exposure. Some heavy metals like
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aluminum can be removed from the body while others accumulate and lead to chronic health
effects. Heavy metals may act as pseudo elements in the body and interfere with metabolomic
processes, generate free radicals, and produce oxidative stress. [18].
Arsenic is known to alter protein and some enzyme function due to a high affinity to sulfhydryl
groups and can bind to reduced cysteines [19]. Enzymes that contain hydroxyl and thiol groups,
such as pyruvate dehydrogenase (PDH), can be deactivated through arsenic binding [20]. PDH is
part of the pyruvate dehydrogenase complex (PDC), which plays an important role by controlling
the rate of pyruvate entry into the tricarboxylic acid cycle (TCA) by converting it into acetyl
coenzyme A (Acetyl-CoA). PDC is the limiting step in the TCA cycle by funneling pyruvate into
the TCA cycle. Arsenic is shown to substitute for the phosphate in ATP, which can potentially
lead to a disruption to energy metabolism [21]. These effects, once built up, can lead to cell death
or metabolic dysfunction. Energy metabolism is very important in the brain and its dysfunction
has been linked to neuronal death [22]. Energy metabolism dysfunction is commonly observed in
disorders in the nervous system including psychomotor retardation [23].

3.3 Astrocytes and the Brain
In the case of arsenic, it is believed that the developing brain is more susceptible to arsenic-induced
toxic damage [24]. To that end, it is important to consider how heavy metals disrupt neuron
function or lead to cell death, especially during the developmental stage [25]. Brain development
includes prenatal to early childhood. The formation of neurons, axons, and dendrites occur during
brain development. It also includes building and pruning of synapses located between neurons
[26]. These synapses are key to learning and memory formation. Increase and decrease in synapse
strength is critical to memory storage [27].
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An increasing focus on glial cells and their role in neurological disorders has emerged [28]. The
glial cell astrocytes play an important role in forming and maintaining synapses [29]. Astrocytes
are also located between synapses and maintain and regulate synapse function [30]. Astrocytes
help maintain synapses by regulating levels of metabolites present in the synapse. They help
maintain the synapses between neurons including the removal of excess neurotransmitters, such
as glutamate and GABA [31, 32]. Glutamate is taken in by astrocytes and metabolically converted
to glutamine through glutamine synthetase. Glutamine is than shuttled to neurons, which is
converted back to glutamate in a glutamate/glutamine cycle [33]. Astrocytes also help regulate
nutrients that enter the brain. Astrocyte end feet cover 90% of the blood vesicles in the brain and
assist with the blood brain barrier (BBB) function [34]. These blood vesicles form the BBB, which
is very selective in allowing what crosses into the brain [35].
Astrocytes metabolically process nutrients from the BBB and shuttle them to neurons [36].
Glucose metabolism is of interest in astrocytes. Astrocytes consume glucose glycolytically,
blocking glycolysis had minimal effect on ATP production [37]. Astrocytes take in glucose and
produce pyruvate, which is pooled into cytosol pyruvate, which is converted to lactate and
mitochondrial pyruvate [38]. Astrocytes can also glycolytically produce glycogen and convert it
back to lactate for later use [39, 40].
Mitochondrial pyruvate is also funneled into the TCA cycle. Neurons cannot upregulate glycolysis
due to a lack of 6-phosphotrocto-2-kinase/fructose 2,6-bisphosphatse isoform 3 enzymes [41].
Both neurons and astrocytes express PDC to generate ATP from glucose. While neurons express
PDC at a near maximum capacity, astrocytes tightly regulate PDC [42]. Astrocytes produce and
export a number of TCA intermediates, which get taken up by neurons [43]. 13C glucose has been
used to show that TCA products, including citrate, is funneled to neurons [44].
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Due to astrocytes’ relationship to the BBB, it is one of the first cell types to encounter and respond
to foreign agents. Arsenic has been shown to cross the BBB and the placenta [45]. This suggests
that astrocytes are the first neurological cells to encounter xenobiotics like arsenic. Rodent models
have shown that arsenic can accumulate in the brain, particularly in the pituitary, hippocampus,
thalamus and hypothalamus [46].
Astrocytes have high concentrations of antioxidants, including glutathione and vitamin C, making
them highly resistant to oxidative stress induced by xenobiotics [47]. GSH has also been shown to
catalyze the reduction of peroxides and to form complexes with xenobiotics [48]. GSH is also used
by arsenic (III) methyltransferase (AS3MT), which methylates arsenic in the brain [46]. In
addition, GSH has been shown to form complexes with arsenic as part of the arsenic excretion
process. However, in addition to supporting cells, astrocytes have been known to induce toxic
effects. Astrocytes have been shown to be reactive, including regulating and inducing
inflammation, and can induce cell damage as well as cell repair [49].
Cultured astrocytes have been shown to alter their metabolism when exposed to arsenic notably in
the production of GSH [51]. Glucose metabolism is important in the production of GSH as well as
the formation of many biomolecules. When treated with 3 mM of arsenic for 2 hours there was a
decrease in internal GSH and an increase in external GSH [52]. To observe how arsenic altered
the glucose metabolism, astrocytes were feed 13C labeled glucose. Levels of metabolites derived
from glucose were measured to identify metabolomic pathways that were altered by arsenic
treatment.

3.4 Method and Materials
3.4.1 Chemicals and Reagents.
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Astrocyte Cell Cultures.
All cell culture work was done by Jordan Rose from Dr. Rodrigo Franco Cruz’s lab.
Primary astrocytes were cultured in 100 mm dishes for NMR analysis and 6 well plates for flow
cytometric analysis and cell-based assays. Primary astrocytes were collected from mouse pups,
stored in a cryofreezer, and were thawed on ice before use. Cells were grown in Dulbecco’s
Modified Nutrient Mixture F-12 (DMEM) media with 10% Fetal Bovine Serum (FBS) and 1%
penicillin-streptomycin. The cells were incubated at 37oC and 5% CO2 and the media was changed
every 2-3 days until cells reached 90% confluence. Once the cells reached confluence, the media
was replaced with the treatment media. Treatment media consisted of DMEM with the measuredout arsenic dosage as well as replacing

12

C-glucose with

13

C6-glucose for

13

C-labeling of the

metabolome. The cells were treated for 12 hours followed by extraction of the metabolome.

3.4.2 Preparation of Metabolomics Samples for NMR Analysis.
Prior to cellular extraction, 1 mL of media was collected of and used to measure extracellular
metabolites. Extracellular metabolites extracted by centrifuging the collected media for 5 minutes
at 15,000 g at 4°C and collecting the supernatant. Intracellular metabolites were collected from the
cell lysate. The cells were first washed twice with 5 ml of phosphate buffer. 1 mL of methanol at
-80°C was used to lyse and quench the cells. Cells were then incubated for 15 minutes at -80°C to
facilitate the lysis. Cells were then detached with a cell scraper and confirmed with an inverted
microscope. The process was repeated if cells remained attached. The methanol and cell debris
were collected in 2 mL microcentrifugation tubes and centrifuged for 5 minutes at 15,000 g at 4
o

C to pellet the cell debris. The methanol supernatant was collected. The cell debris was extracted

with a 80%/20% mixture of methanol/water, centrifuged for 5 minutes at 15,000 g at 4oC, and the

96

supernatant collected. The process was repeated with 100% water. The three supernatants were
combined, evaporated in a RotoSpeed vacuum to remove the methanol. and then lyophilized to
dryness. The samples were reconstituted for NMR analysis with the addition of 500 uL of 50 mM
phosphate buffer in D2O at pH 7.2 (uncorrected) with 500 M sodium-3-trimethylsilylpropionate
(TMSP) used as an internal chemical shift standard.

3.4.3 NMR Data Collection and Processing.
NMR spectra was collected on a Bruker AVANCE III-HD 700 MHz with a 5 mm quadrupole
resonance QCI-P cryoprobe (1H, 13C,15N and 31P) with z-axis gradients. Samples were collected at
300K using a SampleJet automated sample changer and Bruker ICON-NMR software to automate
data collection. The 1D 1H experiments were collected with 128 scans and 4 dummy scans. There
were 32,768 data points collected with a spectral width of 11,160 Hz with a 2s relaxation delay.
2D 1H-13C HSQC spectra were collected with 128 scans and 16 dummy scans. In the direct
dimension, there were 1024 points and a spectral width of 9,090 Hz. In the indirect dimension,
there were 128 points and a spectral width of 29,165 Hz. NMR data was Fourier transformed, auto
phased, and referenced to TMSP with NMRpipe. NMRViewJ Version 98 was used to peak pick
and to quantify peak changes. The NMR data sets was normalized to the total peak intensity.

3.4.4 Metabolite identification.
Chemical shifts were assigned using Platform for RIKEN Metabolomics (PRIMe)
(http://prime.psc.riken.jp/) with a 0.05 ppm and 0.1 ppm error range for 1H and 13C chemical shifts,
respectively. Metabolite identity was manually confirmed with the Human Metabolome Database
(HMDB) (https://hmdb.ca/) [54]. Metabolite concentrations were measured from peak intensities.
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All metabolite concentrations were normalized to TMSP (500 M). For metabolites with multiple
peaks, intensities were averaged after normalization.

3.4.5 Statistical Analysis and Data Processing.
To measure the effect of arsenic, metabolite levels of treated samples were compared to untreated
control samples. Fold changes were calculated between treated and untreated samples. Student’s
t-test was used to verify statistical significance followed by a Benjamin-Hochberg multiple
hypothesis correction to account for false discovery rate [53]. A corrected p-value < 0.05 was
considered statistically significant.

3.5 Results and Discussion
Astrocytes respond to arsenic in a time and concentration dependent fashion. Astrocytes exposed
to arsenic have been shown to have decreased viability. Exposure of cultured cells at 1 mM for 24
hours resulted in decreased cell viability [55].
To observe the effect arsenic on glucose metabolites, intermediate and product metabolites were
measured by NMR. 13C Glucose was fed to astrocytes and metabolite products were quantified
in both the intracellular and extra cellular space. Figure 3.1 is an example HSQC and shows some
of the metabolites identified by chemical shifts. We looked for changes which upon treatment
showed consistent increases or decrease across replicates. Figure 3.2 shows fold change in
metabolites. Upon treatment with arsenic, there was an observed increase in glycolysis
intermediates, fructose-6-phosphate at and 3-Phosphate-Glycate. However, there was a decrease
in glycolytic products lactate and glycogen precursor Uridine diphosphate glucose (UDP-glucose).
Figure 3.2 shows the fold changes for metabolites identified both intracellular and extra cellular.
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This suggests that glycolysis is upregulated but funneled into pyruvate production rather than
lactate production.

Figure 3.1: 2D 1H-13C HSQC spectra from astrocytes cell extract following treatment with 10 μ
of As2O3. Highlighted are some of the metabolites identified based on chemical shifts.

Decreased lactate production is observed when astrocytes experience oxidative stress. It has been
observed that peroxide induced oxidative stress exposure decreased lactate production. Measuring
13

C enrichment levels show that it was not a shift in carbon sources but a decrease in overall

production [56]. At low levels of arsenic exposure, astrocytes with 0.1 mM and 0.3 mM arsenic
stimulated GSH export and glycolic flux resulted in excess lactate production [51]. However, we
observed it is likely that astrocytes divert glucose from glycolytic lactate production to pyruvate
production for use in the TCA cycle at high levels of arsenic exposure. Lactate has been theorized
to be funneled into the TCA cycle of neurons as a carbon source [43]. However, lactate also
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modulates receptors and channels in neurons [57].
TCA cycle intermediates are difficult to measure after long treatments due to the cyclic nature of
metabolic processes. Instead, the focus was shifted to the products. Figure 3.2 shows metabolites
with significant fold change in both the intercellular and extracellular space. We observed a major
increase in glutamate (2.33, 36.35 ppm) in the extracellular and a matching decrease in the
intercellular concentration. We also observed a decrease in extracellular metabolites lactate and
citrate at high doses. Figure 3.3 shows where these metabolites are in the glycolic and citric acid
cycle. Increases in the export of glutamate due to arsenic exposure has been previously observed
[58, 59].

Figure 3.2: Relative fold change of metabolites detected in 2D 1H-13C HSQC spectra. Fold
changes represent metabolite levels compared to an untreated control. Error bar represents standard
deviation. Astrocytes cells were treated with 0 (black), 2, (grey) 5 (dark grey) and 10 (white) M
of As2O3. All detected metabolites are derived from 13C6-glucose.
After being converted into pyruvate, glucose was funneled into the TCA cycle. The intermediates
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Figure 3.3: Summary of change in metabolism of 13C glucose in astrocytes following arsenic
treatment. The metabolic pathway shows glucose metabolized through glycolysis and the TCA
cycle. Gray colored metabolites were not detected. Black colored metabolites were identified but
had no significant change. Green colored metabolites had a significant decrease relative to
untreated astrocytes. Red colored metabolites had a significant increase relative to untreated
astrocytes.
Treating astrocytes with 1.5 to 30 μM of arsenic resulted in decrease in the expression of glutamate
transporters in astrocytes, which resulted in a decrease in glutamate uptake [60]. Glutamate is a
key component in GSH. It has been previously shown that GSH catalyzes the condensation of
ammonia and glutamate, which reduces toxic levels of glutamate and ammonia [61]. Astrocytes
exposed to hydrogen peroxide has been shown to reduce glutamine levels, suggesting a disruption
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in GSH [62]. Glutamate export is also important to the import of cystine through the xCT transport
[63]. Studies have shown that the production of GSH results in the consumption of cystine [64].
Glutamate export is a response to the import of cystine into the cell to upregulate GSH production.
This may result in neuron death due to an inability to produce GSH, leading to oxidative stress
[65].
A decrease in citrate was also observed at a high level of arsenic exposure. A decrease in citrate
production has been observed with aluminum, although this was likely due to the binding to
aluminum and prevention of transport [66]. Citrate is a TCA intermediate and could act as a
possible carbon source for ATP production in neurons. Citrate has been speculated to chelate
calcium and magnesium, and modulate glutamate receptors [67].

3.6 Conclusion
Astrocytes being a one of the larges types of glial cells play a large and diverse role in the brain.
They have been shown to metabolically support neurons, including maintaining homeostasis by
metabolically producing molecules that support neurons. However, they have also been shown to
have negative impacts on neurons. Astrocytes have been known to produce inflammatory products
such as cytokines in response to stressors [68]. There is also the consideration that exposure to
toxins can hijack glucose metabolism to shift focus to protective GSH production.
Overall, we observed a decrease in glucose products specifically lactate and citrate as well as an
increase in glutamate. It is possible that the production of GSH alters carbon metabolism away
from energy production towards antioxidant production. Decreased TCA intermediates could
deprive neurons of a carbon source. Additionally, increased consumption of cystine could reduce
the pool available to neurons resulting in oxidative stress [65]. However, it is important to note
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that these metabolites also function to modulate receptors. Lactate has been shown to bind to
synaptic receptors connected to synaptic plasticity [57]. Lactate has suggested to be a key
metabolite in memory formation due to high brain energy demands [69]. Westergaard suggested
that citrate plays a role in NMDA glutamate receptor by chelation of Zn2+ [67]. Many of these
effects could lead to dysfunction or cellular death of neurons.
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Chapter 4

4. Geographical Analysis of Wine
4.1 Introduction to Wine Science
Since wines discovery, continuous efforts have been made to improve its quality, taste and
production levels. Wine is a complex mixture consisting of 86% water, 12% glycerol and
polysaccharides, 0.5% acids, and 0.5% volatile compounds [1]. This mixture is shaped by the
complex process of wine making, from grape growth to fermentation. For example, phenolic
compounds (hydroxy-substituted benzene rings) are developed in grapes and are largely
responsible for the taste and color of wine. Each phenolic compound comes from a different part
of the grape and plays a unique role in the overall quality of the wine. For example, flavonols are
phenolic compounds found in the seed and skin of the grape, where production is stimulated by
UV light exposure. Flavonols can increase the wine’s color intensity and are highly correlated with
the market price of wine. Anthocyanins are another class of phenolic compounds responsible for
the color of red wine [2]. Yeast fermentations develops wine further by consuming grape products
and converting them into new chemicals. There are two key steps to wine fermentation, alcoholic
fermentation and malate fermentation, which may occur simultaneously or sequentially. Alcoholic
fermentation converts sugars, mainly glucose and fructose, to ethanol and carbon dioxide. Malic
fermentation, while not technically fermentation, converts malic acid to lactic acid [3]. Overall,
the taste, smell and texture of wine, and correspondingly its value, is defined by the wine’s
chemical composition, which is impacted by the environment, climate and wine-making process.
Accordingly, there is a long history and interest in correlating the chemical composition of wine
with its quality and production.
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In 1866, In the late 1970s, Shauils and Smart evaluated canopy management and found ways to
increase the production of high quality grapes [4]. As scientific methods improved, wine science
was better able to pinpoint the specific compounds that contribute to wine flavor. In the late 19 th
century, many of the phenolic compounds in wine were identified and the structures determined
[5]. Thus, phenolic compounds can now be rapidly quantified from individual wine samples [6].
In this manner, the factors that contribute to high-quality wines may be assessed by studying the
wine’s phenolic profile. Furthermore, by identifying and quantifying the different compounds in a
wine, the resulting chemical profile may be used to ensure wine quality. Alternatively, wine
chemical profiles may be used to evaluate different yeast strains to identify which strains produced
the desired result [7]. Phenolic compounds are also of interest to human health. Their antioxidant
and anti-inflammatory capacities may present potential health benefits [8]. Chemical or phenolic
profiles are frequently used to authenticate wines or identify its terrior [9]. Terroir defines all the
factors or variables (i.e., soil composition, sun exposure, rainfall, etc.) that impact how the wine
was produced by a vineyard. Alternatively, terroir is a measure of the effect of the environment on
the wine [10].

The profiling of the chemical composition of wine may be accomplished in several ways. Assay
tests are frequently used to quantify a specific class of chemicals or just a few particular
compounds. Assays allow for the rapid testing of many wine samples while providing accurate
analysis. For example, an assay can monitor the fermentation process by specifically measuring
ethanol production [11]. Other assays may be used to identify errors or problems with the
fermentation process, such as observing the accumulation of acetic acid. The production of excess
acetic acid leads to wine with an undesirable sour taste [12]. Similarly, the Fox-1 assay targets
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tannins, which are often associated with wine astringency [12]. Of course, any assay limited to a
single molecule will be restricted to what can be learned about the system.

As an alternative to targeted assays, analytical techniques can offer a broader coverage of wine
metabolites. The simultaneous quantification and identification of the large number of compounds
present in wine has an inherent and distinct value for characterizing authenticity [13]. Mass
spectrometry (MS) coupled with liquid chromatography (LC-MS) or gas chromatography (GCMS) may rapidly quantify the entire metabolic or chemical profile of wine. MS is a popular method
for detecting any ionizable compound, which is further enabled by the availability of large
reference databases for ready metabolite assignments. The exact mass, retention time and
fragmentation patterns are used to identify metabolites by matching experimental values to
database reference values. For example, LC-MS has been used to measure tannins in red wine to
characterize its age [14]. NMR has also been effectively used to profile wines, grapes, and the
products before, during and after fermentation. NMR detects 1H and

13

C chemical shifts, which

makes it useful for identifying and quantifying the organic compounds in wine. For example, NMR
was used to measure the compounds in the pulp, skin, and the seeds from grapes to evaluate quality.
The pulps were differentiated by levels of alanine and citrate [15]. NMR was also used to compare
different strains of yeast, it was noted that yeasts that fermented wine faster produced higher levels
of succinate and glycerol [16]. Port wines of different ages were compared by NMR and it was
observed that aged wines had lower levels of succinate acid, pyruvic acid -butyric acid and proline
[17].
Chemical or metabolic profiles are useful for evaluating wines, but sample variation is frequently
a problem with commercial wines, Herein, we describe the chemical characterization of various

113

Pinot Noir (PN) wines produced by a number of California and Oregon vineyards. A chemical
profile can be used to measure the environmental impact on PN wines and to differentiate different
PN wines. A differential sensing assay that provides a phenolic profile was combined with
untargeted one-dimensional (1D) 1H NMR data to compare PN wines from different vineyards,
vintages, and wine regions. Wines were successfully identified based on vineyard of origin using
a combination of univariate and multivariate statistical analysis.

4.2 Materials and Methods
4.2.1 Chemicals
Deuterium oxide (99.9% D) was obtained from Sigma Aldrich (Milwaukee, WI). 3-(trimethylsilyl)
propionic-2,2,3,3-D4 acid sodium salt (98% D) (TMSP-D4) was purchased from Cambridge
Isotopes (Andover, MA). Potassium phosphate dibasic salt (anhydrous, 99.1% pure) and
monobasic salt (crystal, 99.8% pure) were purchased from Fisher Scientific (Fair Lawn, NJ).

Wine grapes (Vitis vinifera L. cv. Pinot noir clone Dijon 667) from fifteen different vineyard sites
along the West Coast of the United States were harvested at similar sugar concentration of 24 Brix
between 13 Aug to 15 Sept 2015 and between 25 Aug to 21 Sept 2016 (Table 4.1). Eight American
Viticultural Areas, which span a latitudinal distance of approximately 1450 km, are represented in
this experiment: Santa Rita Hills (SRH), Santa Maria Valley (SMV), Arroyo Seco (AS), Carneros
(CRN), Sonoma Coast (SNC), Russian River Valley (RRV), Anderson Valley (AV), and
Willamette Valley (OR). Table 4.1 lists the selected vineyards, the wine region and the nearest
county.
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County
Wine Region
Vineyard
Sonoma
Sonoma Coast
Annapolis
Sonoma
Sonoma Carneros
Cloud Landing
Sonoma
Sonoma RRV
Carneos Hills West
Sonoma
Sonoma RRV
Ross
Sonoma
Sonoma RRV
Bones
Sonoma
Sonoma RRV
Bloomfield
Mendocino
Anderson Valley
Boone Ridge
Mendocino
Anderson Valley
Maggy Hawk
Monterey
Arroyo
Panarama 5A
Monterey
Arroyo
MSA
Santa Barbara
Santa Maria Valley
Nielson
Santa Barbara
Santa Maria Valley
Rice/Cambria
Santa Barbara
Santa Maria Hills
Radian
Marin County
Willamette Valley
Gran Moraine
Marin County
Willamette Valley
Zenna West
Table 4.1: List of wines and vineyards. The nearest county was used to group wine regions.
Counties Sonoma, Mendocino, Monterey, and Santa Barbra are located on the cost of California
while Marin County is in Oregon.
4.2.2 Winemaking
Grapes were fermented in 200 L stainless steel fermenters at the UC Davis Teaching & Research
Winery. Primary fermentation was initiated by inoculating with Lalvin RC212 (Lallemand) after
warming the must to 21°C. The fermentation temperature was held a 21°C for two days after
inoculation, and subsequently allowed to rise to 27°C where it was held for the remainder of
primary fermentation. Wine was separated from the red grape skins by using a basket press on the
ninth day after grapes were placed into the fermenter.

4.2.3 Differential Sensing Method
The indicators Chrome Azurol S (CAS) (purity 65%), Bromopyrogagllol Red (BPR), and
Pyrocatechol Violet (PCV) (purity 100%) were purchased from Sigma-Aldrich (Saint Louis, MO).
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Nickel chloride hexahydrate (purity 99.7%), copper (II) sulfate (purity 99.2%), and HEPES buffer
were purchased from Fisher Scientific (Hampton, NH). Solid phase peptide synthesis reagents
were purchased from P3 BioSystems (Louisville, KY). Peptides were synthesized using standard
SPPS and a CEM Liberty Blue Automated Microwave Synthesizer, (Matthews, NC, USA).
Absorbance values were recorded using a Spectra Max Plus 384 plate reader (Molecular Device
Inc.)

4.2.4 Array and Indicator Displacement Assay
A library of nine peptide-based sensors were used for the construction of the differential sensing
(DS) array. Each ensemble was composed of a histidine peptide, a divalent metal and a
colorimetric indicator. The peptides: WAHEDEFF (TT2), FHFPHHF (SEL1), and WEEHEE
(RN8) were used to prepare the same peptide-metal-indicator ensembles (MM1-MM9) and
corresponding binding ratios were previously reported [18,19]. Arrays were prepared in Fisher
Scientific non-treated 96-well plates with flat bottom and clear polystyrene. Final well-plate
solutions of peptide ensembles and wine concentration of 1% (v/v) were prepared using 50 mM
HEPES in ethanol, 1:1 (v/v), pH = 7.4). Absorbance endpoint-values due to the displacement of
each indicator by the tannins were measured at 430 nm, 444 nm, and 560 nm corresponding to the
λmax of free CAS, PCV, and BPR, respectively. Eight replicates were performed to ensure
reproducibility. Controls consisted of a column of wine alone and a column of the ensemble alone
in each plate. Two experimental replicates of the full array were performed in 2017 using the wines
from 2015 vintage and in 2018 using wines from the 2016 vintage, respectively.

4.2.5 NMR Sample Preparation.
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Wine was removed for amber vials via a syringe immediately before preparing the NMR samples.
Each NMR sample was prepared by adding 15 µL of 50 mM phosphate buffer prepared in D2O at
pH 7.2 (uncorrected) with the addition of 50 µM of TMSP-D4 as an internal chemical shift
standard to 150 µL of wine. Eight analytical replicates were prepared for each wine for a total of
120 NMR samples.

4.2.6 NMR Data Collection and Processing.
NMR spectra were collected on Bruker a AVANCE III 700 MHz spectrometer equipped with a 5
mm quadrupole resonance QCI-P cryoprobe™ (1H,

13

C,

15

N and

31

P) with a Z-axis gradient. A

SampleJet automated sample changer system with Bruker ICON-NMR™ software and an
automatic tuning and matching accessory was used to automate the data collection.

A 1D 1H NMR spectrum with a presaturation pulse and a NOESY pulse sequence was collected
for each of the 120 wine samples. The Bruker automation program, Multisupp, was used to
suppress the multiple solvent peaks resulting from the presence of water and ethanol in the sample.
Multisupp automatically identifies and suppresses the most intense peaks in the NMR spectrum.
For this experiment, one peak at 4.7 ppm due to water and the three peaks at 1.3, 2.7. and 3.7 ppm
due to ethanol were suppressed. The 1D 1H NMR spectra were collected at 300K with 65K points,
a spectral width of 14705 Hz, 128 scans, 4 dummy scans, and 4s relaxation delay.
1D 1H NMR spectra were batch processed and analyzed using our NMR metabolomics toolbox,
MVAPACK [20]. The spectra were Fourier transformed, auto phased and referenced to TMSP at
0 ppm. Regions of the spectra containing residual water and TMSP were removed. The spectra
were normalized using probabilistic quotient normalization and unit-variance scaled. Uniform bins
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of the 1D 1H NMR dataset were exported as a matrix from MVAPACK.

4.3 Statistical Analysis.
4.3.1 PCA analysis
PCA models were generated from the binned NMR data, the DS array data, and the combined
NMR and DS array data set. PCA models were generated with MVAPACK [13] using 3 principal
components. Dendrogram were created from the associated PCA scores plot with all wines
separated by a Mahalanobis distances depicted as p-values [21,22]. A p-value < 0.05 was deemed
to be statistically significant.

4.3.2 ROC analyses
The combined NMR and DS array data set was processed in MetaboAnalyst 4.04
(https://www.metaboanalyst.ca/) to obtain multivariate ROC curves [23]. The dataset was range
scaled and ROC curves generated using a support vector machine algorithm. A one versus all
comparison was made for each individual wine.

4.4 Results
4.4.1 NMR Data Collection for Wine Samples
To optimize data collection, multiple methods of NMR data collection and data processing were
evaluated. Wine contains relatively high concentrations of water and ethanol, while containing low
concentrations of other compounds, such as phenolic, which are key to characterizing wines. In
order to fully chemically profile each wine, it is essential to detect metabolites with low
concentrations in the 1D 1H NMR spectrum. The large dynamic range between the solvent peaks
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and the wine metabolites posed a serious challenge. Therefore, an initial goal was to suppress the
high-intensity solvent peaks while preserving the NMR peaks from the low concentration
metabolites. Furthermore, the experimental design focused on minimizing sample preparation and
handling to reduce the introduction of error.

Solvent signals are often removed by lyophilization. However, we observed residual amounts of
solvent after lyophilizing the wine samples and reconstitution into buffered D2O. Therefore, the
water and ethanol signals were also suppressed during NMR data collection. The Bruker program
Multisupp was used, which suppresses the most intense peaks in the NMR spectrum. Accordingly,
the four largest peaks corresponding to the residual water and ethanol resonances were
simultaneously suppressed. A dramatic improvement in the spectral quality was achieved as
evident by the observation of weak metabolite peaks near the base line that were not visible prior
to solvent suppression. Figure 4.1 shows a comparison between the suppressed and unsuppressed
1D 1H NMR spectra for the wine from Nielson. In total, 120 NMR spectra were collected. While
the baseline in the multi suppressed NMR spectra was not stable across the data set and required
baseline corrections, there were significantly more metabolites detectable following solvent
suppression. Specifically, an abundance of low level metabolites were observed in the NMR
spectral regions between 0 to 3 ppm and between 5.5 to 8 ppm, which corresponds to organic acids
and carbohydrates, respectively.

Other experimental protocols were evaluated to assess which approach preserved the most
metabolites detected in the 1D 1H NMR spectrum. For example, samples were prepared under both
atmospheric conditions or a nitrogen atmosphere. No difference was observed between samples
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prepared in the presence or absence of oxygen. Wine samples were also adjusted to a common pH
by the addition of a D2O phosphate buffer at pH 7.2. Not surprisingly, the addition of a buffer
resulted in a better comparison between NMR spectra. Any residual pH variation was accounted
for by aligning the NMR spectra in data processing.

Figure 4.1: A comparison between a multi-suppressed 1D 1H NMR spectrum (red) and a water
suppressed spectrum (blue) for wine from Nielson. (A) The expanded region of the 1D 1H NMR
spectra between 6 ppm and 9 ppm highlights phenolic compounds. (B) The expanded region of
the 1D 1H NMR spectra between 3 ppm and 5 ppm highlights sugar compounds. (C) Overlay of
the complete 1D 1H NMR spectra highlighting the dramatic improvement resulting from
successful solvent suppression.

4.4.2 Overview of the Statistical Analysis of NMR and DS array data sets
Combining the NMR and DS array data sets provides an expanded view of the entire wine
metabolome [24]. Simply, the NMR data set provides an untargeted characterization of the
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metabolome; in which, only the relatively high concentrated metabolites (> 3 M) are detected.
Conversely, the DS array data set is only providing a profile of the phenolic compounds present in
the wine sample. Thus, the NMR and DS array datasets are highly complementary. The NMR
spectral data set was UV scaled and then exported as a matrix to match the structure of the DS
assay data. The NMR data matrix was generated by uniformly binning the 1D 1H spectra such that
the resulting data matrix consisted of an integrated intensity over the binned ppm range. The NMR
matrix for each wine sample consisted of 8 technical replicates. The DS assay data set also contains
8 technical replicates. The NMR and DS assay data sets were analyzed individually and as a
combined multiblock data set. The combined data set was used to identify which spectral features
was best at categorizing each wine.

4.4.3 Variations in Vineyard Climates
To study the impact of climate on each wine’s metabolome, environmental statistics were obtained
from the Everyvine (http://www.everyvine.com/) database. Everyvine provides climate conditions
for various wine regions by collecting data from individual vineyards and determining an average
from the collated climate data. Climate data was assembled for the wine regions of interest with
the assumption that a vineyard in a defined region will have a similar climate. The average sunlight,
average high and low growing temperatures, and the total rain fall were measured during each
growing season. Heliothermal or Huglin index values were also reported by Everyvine. Huglin
index is a vineyard heat index that sums all temperatures above 10 oC between April and September
[25]. The Huglin heat sum index relies on the daily median and maximum temperatures, and a
parameter (k) based on the latitude of the vineyard (eqn 4.1):
∑𝒏𝒅=𝟏 𝒎𝒂𝒙 [

𝑻𝒎𝒊𝒏 −𝟏𝟎+𝑻𝒎𝒂𝒙 −𝟏𝟎
𝟐

, 𝟎] 𝒌

(4.1)
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Equation 2.1: The calulation for the Huglin heat sum index where k factor is adjusted for latitude
[26].
However, only averages climate values were available, which does not account for seasonal
variation. Since the Pinot noir wines were derived from the same clone (Dijon 667), a major source
of metabolome variations may be attributed to climate differences. In this regards, climate data
was used to determine if wines that exhibited a similar metabolome also shared similar climate
data. Table 4.2 lists the available climate data for the wine regions used in this study. Climate data
was divided into low medium and high based on the regions selected. For the Huglin Index low
is considered below 2000, with high above 2190. For average high temperature is considered
below 24.5°C and high above 25.5. For average low temperature low is considered 8.5°C and high
above 9.25C. Rain fall was considered low below 3 in and high above 6in.
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Vineyard

Wine Region

Huglin
Index

Average
High (°C)

Average
Low
(°C)
9.11
9.89

Rain
Fall
(in)
6.24
4.14

Annapolis
Sonoma Coast
2146.3
25.33
Cloud
Sonoma Carneros 2224.94
25.67
Landing
Carneos Hills Sonoma RRV
2197.24
25.78
8.83
5.92
West
Ross
Sonoma RRV
2197.24
25.78
8.83
5.92
Bones
Sonoma RRV
2197.24
25.78
8.83
5.92
Bloomfield
Sonoma RRV
2197.24
25.78
8.83
5.92
Boone Ridge Anderson Valley
2185.79
25.67
8.50
7.55
Maggy Hawk Anderson Valley
2185.79
25.67
8.50
7.55
Panarama 5A Arroyo
2034.7
25.00
9.17
1.96
MSA
Arroyo
2034.7
25.00
9.17
1.96
Nielson
Santa Maria Valley 1862.37
23.72
9.50
2.8
Rice/Cambria Santa Maria Valley 1862.37
23.72
9.50
2.8
Radian
Santa Maria Hills
1862.37
24.28
9.83
2.54
Gran Moraine Willamette Valley
1749
21.78
8.11
14.13
Zenna West
Willamette Valley
1749
21.78
8.11
14.13
Table 4.2: Average Climate Conditions Local environmental and climate information was
generated from averaging vineyard climate data submitted to Everyvine. Climate data was
collected September of 2019. The Huglin index acts as a measure of heat and is the sum of the
temperatures above 10°C during the growing period (see eqn. 4.1).

4.4.4 Global Comparison of PN using Metabolic Profiles
An overall PCA model was generated that included all 15 wines. A PCA model reduces a large
multivariate data set into a limited number of principle components (usually 2 to 9) and identifies
the unique spectral features that distinguishes the groups. A PCA model is a common approach for
viewing wine classification data and is frequently used to provide an overview of the global
similarity or differences between the individual wines. A PCA model is usually presented as a
scores plot where each replicate (i.e., 1D 1H NMR spectrum or DS assay array) is presented as a
single point in the two- or three-dimensional plot. The relative similarity or difference between
each replicate and/or group is assessed by how close or how far each data point or group cluster is
from each other.
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PCA models were generated from the 1D 1H NMR data set, the DS assay data set, and the
combined NMR and DS array data set. A PCA model was generated from the data sets with
replicates grouped by the individual vineyards (15 groups) or the vineyards classified by wine
region (8 groups, Table 4.2). The quality of the resulting PCA models were assessed by the
reported R2 and Q2 values. Typically, a good model has an Q2 and R2 close to 1, with R2 > Q2. A
high R2 value indicates that the data fits the model well. A high Q2 value indicates a good
reproducibility of the model. Q2 measures the amount of variance in fitting the held-out data to the
model.
PCA models could not be generated using the NMR and/or DS assay data grouped by wine region.
This indicates that there was too much variation in the wine region defined data sets to generate a
valid PCA plot. However, a PCA model was generated from the NMR and/or DS assay data
grouped by individual vineyards. The resulting PCA models could separate each wine.

4.4.5 DS Assay PCA Model
The PCA model generated from the DS assay data set (Figure 4.2A) indicated that most of the
individual vineyards formed a distinct group from the other vineyards in the scores plot. The
associated dendrogram (Figure 4.2B) also indicated a clear separation between most of the
vineyards. Thus, despite the wines being derived from the same Pinot noir clone Dijon 667,
environmental and climate factors, among others, define the chemical profile of the wines.

The dendrograms were produced from the associated PCA scores plot based on a matrix of
Mahalanobis distances between each group. Each node in the dendrogram was labeled with a pvalue indicating the statistical significance of the group separation. Overall, the dendrogram
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clusters the vineyards into 4 groups containing between 3 to 5 vineyards within each cluster. A
few wines did significantly overlap (p-values > 0.05). Notably, wines from vineyards in the same
region did not all cluster together, which is consistent with the failure to generate a PCA model
based on wine regions

Wines from Bloomfield, Annapolis, and Cloud Landing did cluster together, which could be due
to the fact that these vineyards are all located in Sonoma County. However, the wines are in distinct
wine regions. Bones and Carneros Hills West clustered together and do belong to the same wine
region, Sonoma RRV. In fact, the wines were statistically indistinguishable (p-value 0.33).
However, the other vineyards in Sonoma RRV, Ross and Bloomfield, were found in other clusters.
Boone Ridge and Nielson also clustered together and were statistically indistinguishable (p-value
0.23). These wines were not in the same wine region and do not share climate averages as observed
from the Everyvine data. This suggests that general location and/or climate data are insufficient to
explain relative vineyard groupings. Other terroir factors, such as soil conditions, or wine
processing protocols, may better explain the relative clustering of vineyards.
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Figure 4.2: PCA model (R2 .787, Q2 .634 generated from the DS assay data. (A) PCA scores plot
showing all 15 wines where Nielson (red), Rice/ Cambria (Orange), Radian (Yellow), Panorama
5A (Lime Green), MSA ( Light Green), Annapolis (Green), Cloud Landing (Green), Carneros
Hills West (Teal), Ross (Cyan), Bones (Blue), Bloomfield (Navy Blue), Boone Ridge (Violet),
Maggy Hawk (Purple), Gran Moraine (magenta), Zena West (Pink). Each ellipse corresponds to
95% confidence interval for a normal distribution. (B) The dendrogram was generated from the
PCA scores plot in A and is based on a matrix of Mahalanobis distances between each wine group
in the PCA scores plot. Each node in the dendrogram is labeled with a pairwise p-value.

4.4.6 NMR PCA Model
The PCA model generated from the 1D 1H NMR data (Figure 4.3) clustered similarly to the DS
assay data. Most of the individual vineyards formed a separate and distinct group in the PCA scores
plot. The associated dendrogram clustered the wines into 5 distinct groups containing between 2
to 4 wines each. Like the DS assay data, the vineyard grouping was not determined by wine region
or climate data. Notably, the relative wine clustering differed between the NMR and DS array data
sets. For example, Bones is now nearly overlapped with Zena West (p –value 0.04) instead of
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Carneros Hills West. Similarly, Boone Ridge is close to, but not identical (p-value 2.6x10-4) to
Cloud Landing instead of Nielson. While Ross and Bloomfield are still clustered together they are
now grouped with Annapolis. They are all from the Sonoma county, but not the same wine region.
All of the wines were more distinguishable based on the NMR data set (p-values < 0.05). The pair
of wines with the highest p value (p-value 0.05) was Panorama 5A and Radian, which are from
the Santa Barbra County, but not from the same wine region.
Wines from Bloomfield, Annapolis, and Cloud Landing did cluster together, which could be due
to the fact that these vineyards are all located in Sonoma County. However, the wines are in distinct
wine regions. Bones and Carneros Hills West clustered together and do belong to the same wine
region, Sonoma RRV. In fact, the wines were statistically indistinguishable (p-value 0.33).
However, the other vineyards in Sonoma RRV, Ross and Bloomfield, were found in other clusters.
Boone Ridge and Nielson also clustered together and were statistically indistinguishable (p-value
0.23). These wines were not in the same wine region and do not share climate averages as observed
form the Everyvine data. This suggests that general location and/or climate data are insufficient to
explain relative vineyard groupings. Other terroir factors, such as soil conditions, or wine
processing protocols, may better explain the relative clustering of vineyards.
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Figure 4.3: PCA model (R2 .812 Q2 .77 generated from the 1D 1H NMR data. (A) PCA scores
plot showing all 15 wines where Nielson (red), Rice/ Cambria (Orange), Radian (Yellow),
Panorama 5A (Lime Green), MSA ( Light Green), Annapolis (Green), Cloud Landing (Green),
Carneros Hills West (Teal), Ross (Cyan), Bones (Blue), Bloomfield (Navy Blue), Boone Ridge
(Violet), Maggy Hawk (Purple), Gran Moraine (magenta), Zena West (Pink). Each ellipse
corresponds to 95% confidence interval for a normal distribution. (B) The dendrogram was
generated from the PCA scores plot in A and is based on a matrix of Mahalanobis distances
between each wine group in the PCA scores plot. Each node in the dendrogram is labeled with a
pairwise p-value.

4.4.7 Multiblock PCA Model
Unexpectedly, the multiblock-PCA (MB-PCA) model generated from the combined NMR and DS
array data did not perform as well as the individual data sets. Very few vineyards were clearly
separated in the MB-PCA scores plot (Figure 4.4A).
In fact, the pairwise comparison of six vineyards yielded p-values > 0.05 indicating no difference
in the chemical profile. Bones, Carneos Hills, and Gran Morane could not be distinguished by the
MB-PCA model. The Bone Ridge, Nielson, and Zena West wines also were indistinguishable.
These wines do not share similar climate or locational data. The associated dendrogram clustered
the wines into 4 clusters containing between 3 to 5 wines each. Again, there was no similarity in

128

the clustering patterns between the three PCA models (Figures 4.2 to 4.4), suggesting unique, nonoverlapping information between the NMR and DS array data sets. Furthermore, since combining
the two data sets resulted in a worse differentiation between the vineyards, the discriminating
spectral features may be anti-correlated. In essence, variance in the NMR data sets partially cancel
variance in the DS array data sets.

Figure 4.4: PCA model (R2 .767 Q2 .623) generated from the combined NMR and DS assay data
set. (A) PCA scores plot showing all 15 wines where Nielson (red), Rice/ Cambria (Orange),
Radian (Yellow), Panorama 5A (Lime Green), MSA (Light Green), Annapolis (Green), Cloud
Landing (Green), Carneros Hills West (Teal), Ross (Cyan), Bones (Blue), Bloomfield (Navy
Blue), Boone Ridge (Violet), Maggy Hawk (Purple), Gran Moraine (magenta), Zena West (Pink).
Each ellipse corresponds to 95% confidence interval for a normal distribution. (B) The dendrogram
was generated from the PCA scores plot in A and is based on a matrix of Mahalanobis distances
between each wine group in the PCA scores plot. Each node in the dendrogram is labeled with a
pairwise p-value.
4.4.8 Wine Classification using a ROC Curve Analysis
Receiver operator characteristic (ROC) curves plot the true positive rate against the false positive
rate. In this regard, a ROC curve is used to ascertain the predictive accuracy of a set of signals or
spectral features by measuring the area under the curve (AUC). The AUC ranges from 1 for a
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perfect prediction to 0.5 for a completely random outcome. A ROC curve was used to identify the
spectral features most useful for wine classification. Specifically, which NMR and/or DS assay
spectral features were better at classifying each wine to a given vineyard? To accomplish this, a
ROC curve was generated that compared each individual wine against the entire collection of PN
wines. A total of 15 ROC curves were produced, one for each wine listed in Table 4.1. Overall,
most ROC curves yielded an AUC close to 1 with the lowest AUC being approximately 0.8. This
indicates that the ROC curves have an accuracy of > 80 to 90% in correctly classifying each PN
wine from the set of 15 wines. Notably, most ROC curves required only 10 spectral features to
achieve the high AUC values. Furthermore, the contribution of NMR and/or DS array spectral
features to the ROC curves varied by wine or vineyard. In some cases, the model was dominated
by NMR spectral features, in other cases by DS array data, or as a nearly equal combination of
both NMR and DS array spectral features. Table 4.3 shows a summary of the ROC curves.
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Wine
Nielson
Rice/Cambria
Radian
Panorama 5A
MSA
Annapolis
Cloud Landing
Canneros Hills
Ross
Bones
Bloomfield
Boone Ridge
Maggy
Hawk/Falk
Gran Moraine
Zena West

Area Under
the Curve
. 736
. 926
. 808
. 766
. 942
. 916
. 904
. 897
. 967
. 847
. 97
. 792
. 907
. 909
. 86

Confidence
Interval
. 376 − .979
. 614 − .995
. 335 − .978
. 496 − .937
. 496 − .937
. 778 − 1
. 642 − .991
. 733 − .933
. 883 − 1
. 35 − 1
. 814 − 1
. 577 − .938
. 606 − 1
. 674 − 1
. 576 − .992

NMR
Components
0
3
1
1
5
1
0
1
4
0
2
4
0
1
2

Assay
Components
5
2
4
4
0
4
5
4
1
5
3
1
5
4
3

Table 4.3: Shows the summary of the ROC curves for each vineyard and includes the area under
the curve and confidence interval for the best performing ROC curve. It also lists the top ten
components used to generate the curves and whither they came from the NMR or Assay data.
Assigning the NMR spectral features to a specific metabolite is challenging. Databases of NMR
reference spectra are incomplete and typically lack secondary metabolites from plants [27].
Instead, databases are primarily populated with metabolites associated with known metabolic
process. So, uniquely modified compounds are lacking in reference databases and NMR chemical
shifts can only be estimated based on similarities to known compounds. Spiking NMR samples
with a commercially available compound can be used to identify and confirm the presence of a
specific metabolite. Of course, there is a very limited availability of known metabolites, especially
in regard to secondary metabolites from plants. The typical 1D 1H NMR spectrum for wine can be
divided into three sections. The 0 to 3 ppm region contains organic acids that includes lactic acid,
acetic acid, citric acid and malic acid. The 3 to 5.5 ppm region contains carbohydrates that includes
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glucose and fructose. The > 5.5 ppm region includes aromatic compounds, such as 2-phenylethanol
[17]. While the compounds contributing to each wine’s chemical profile can’t be individually
identified, the class of compounds may be inferred.

4.4.9 Wine Regions
4.4.9.1 Santa Maria Valley
Santa Maria Valley is in northern Santa Barbara County and San Luis Obispo County in California.
Two vineyards, Nielson and Rice/Cambria, were selected from the Santa Maria Valley wine region
for this study.

For the PCA models using the DS assay data, Nielson clustered with Cloud Landing and Boone
Ridge vineyards. Nielson clustered with Boone Ridge and Panorama 5A using the NMR data.
Similarly, Nielson clustered with Boone Ridge, Zena West, and Panorama 5A using the MB data
set.

For the Nielson ROC curves shown in Figure 4.5, the ROC curve with the highest AUC of 0.802
was generated using 10 variables. The AUC of 0.802 indicates a predictive accuracy of 80% when
differentiating the Nielson wine from the 14 other wines. The ROC curve was defined
predominately with DS array assay data, with MM7 430 being the top feature that distinguished
the Nielson wine.
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Figure 4.5: (A) The ROC curves for the Nielson wine compared against the 14 other wine samples.
ROC curves were generated with MetaboAnalyst (https://www.metaboanalyst.ca/). The graph
shows the ROC curves generated using 5 (orange), 10 (blue), 15 (purple), 25 (teal), 50 (red), and
500 (yellow) variables. (B) The top fifteen variables used to generate the ROC curves. The
frequency represents how often a variable is used in the ROC curve. MM1 to MM7 represents data
from the DS assay, while the numbers (ppm) are binned NMR data.
For the PCA models using the DS assay data, Rice/Cambria clustered with MSA and Ross
vineyards. Rice/Cambria clustered with Radian, Panorama 5A, and Carneos Hills West using the
NMR data. Similarly, Rice/Cambria clustered with Radian, Panorama 5A, and Carneos Hills West
using the MB data set.

For the Rice/Cambria ROC curves shown in Figure 4.6, the ROC curve with a high AUC of 0.926
was generated using 5 variables. The AUC of 0.926 indicates a predictive accuracy of 93% when
differentiating the Rice/Cambria wine from the 14 other wines. The ROC curve used a significant
amount of NMR data. Since the majority of the NMR bins were in the range of 2 to 3 ppm, the
metabolites potentially corresponded to organic acids.
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Figure 4.6: (A) The ROC curves for the Rice/Cambria wine compared against the 14 other wine
samples. ROC curves were generated with MetaboAnalyst (https://www.metaboanalyst.ca/). The
graph shows the ROC curves generated using 5 (orange), 10 (blue), 15 (purple), 25 (teal), 50 (red),
and 500 (yellow) variables. (B) The top fifteen variables used to generate the ROC curves. The
frequency represents how often a variable is used in the ROC curve. MM1 to MM7 represents data
from the DS assay, while the numbers (ppm) are binned NMR data.

4.4.9.2 Santa Maria Hills
Santa Maria Hills is a wine region located in the Santa Ynez Valley in California. Santa Rita Hills
has the highest level of solar radiation at 149663.28 WH/m2. Only one wine, Radian, was selected
from the Santa Maria Hills wine region.

For the PCA models using the DS assay data, Radian clustered with Zena West. Radian clustered
with Panorama 5A and Rice/Cambria using the NMR data. Radian clustered with MSA,
Rice/Cambria, and Ross using the MB data set. The vineyards did not share a similar climate with
Radian.
For the Radian ROC curves shown in Figure 4.7, the ROC curve with a high AUC of 0.86 was
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generated using 15 variables. The AUC of 0.86 indicates a predictive accuracy of 86% when
differentiating the Radian wine from the 14 other wines. The ROC curve was nearly defined by all
DS array data, but an NMR bin was the top feature that distinguished the Radian wine. The ppm
of .9 suggests that this feature is an organic acid.

Figure 4.7: (A) The ROC curves for the Radian wine compared against the 14 other wine samples.
ROC curves were generated with MetaboAnalyst (https://www.metaboanalyst.ca/). The graph
shows the ROC curves generated using 5 (orange), 10 (blue), 15 (purple), 25 (teal), 50 (red), and
500 (yellow) variables. (B) The top fifteen variables used to generate the ROC curves. The
frequency represents how often a variable is used in the ROC curve. MM1 to MM7 represents data
from the DS assay, while the numbers (ppm) are binned NMR data.

4.4.9.3 Arroyo
Arroyo or the Arroyo Grande Valley wine region is located in the San Luis Obispo county of
California Of all the wine regions selected for this study, Arroyo has the lowest rain fall at 1.96
inches per year. Two wines, Panarma 5A and MSA, were selected from the Arroyo wine region.

For the PCA models using the DS assay data, Panorama 5A clustered with Nielson and Boone
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Ridge. Panorama 5A clustered with Radian, Rice/Cambria and Carneros Hills using the NMR data.
Panorama 5A clustered with Zena West, Nielson, Boone Ridge using MB data set. Zena West does
not share environmental conditions with Panorama 5A.

For the Panorama 5A ROC curves shown in Figure 4.8, the ROC curve with a high AUC of 0.841
was generated using 15 variables. The AUC of 0. 841 indicates a predictive accuracy of 84% when
differentiating the Panorama 5A wine from the 14 other wines. The ROC curve used a mixture of
NMR and DS array data, with MM7 560 being the top feature that distinguished the Panorama 5A
wine. The NMR bins covered a range of chemical shifts from 0.9 to 4.3 ppm, suggesting key
metabolites defining Panorama 5A as potentially corresponding to carbohydrates and organic
acids.
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Figure 4.8: (A) The ROC curves for the Panorama 5A wine compared against the 14 other wine
samples. ROC curves were generated with MetaboAnalyst (https://www.metaboanalyst.ca/). The
graph shows the ROC curves generated using 5 (orange), 10 (blue), 15 (purple), 25 (teal), 50 (red),
and 500 (yellow) variables. (B) The top fifteen variables used to generate the ROC curves. The
frequency represents how often a variable is used in the ROC curve. MM1 to MM7 represents data
from the DS assay, while the numbers (ppm) are binned NMR data.
4.4.9.4 MSA
For the PCA models using the DS assay data, MSA clustered with Rice/Cambria and Ross. MSA
clustered with Rice/Cambria and Radian using the NMR data. MSA clustered again with
Rice/Cambria and Radian. using the MB data set.
For the MSA ROC curves shown in Figure 4.9, the ROC curve with a high AUC of 0.96 was
generated using 10 variables. The AUC of 0.96 indicates a predictive accuracy of 96% when
differentiating the MSA wine from the 14 other wines. The ROC curve was nearly exclusively
defined by NMR data. The NMR bins covered a range of chemical shifts from 1.5 to 3.3 ppm,
suggesting key metabolites defining MSA are potentially organic acids.
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Figure 4.9: (A) The ROC curves for the MSA wine compared against the 14 other wine samples.
ROC curves were generated with MetaboAnalyst (https://www.metaboanalyst.ca/). The graph
shows the ROC curves generated using 5 (orange), 10 (blue), 15 (purple), 25 (teal), 50 (red), and
500 (yellow) variables. (B) The top fifteen variables used to generate the ROC curves. The
frequency represents how often a variable is used in the ROC curve. MM1 to MM7 represents data
from the DS assay, while the numbers (ppm) are binned NMR data.

4.4.9.5 Sonoma Coast
Only one wine, Annapolis, was selected from Sonoma Coast region. For the PCA models using
the DS assay data, Annapolis clustered with Bloomfield and Cloud Landing. Annapolis clustered
with Ross and Bloomfield using the NMR data. Annapolis clustered again with Bloomfield and
Cloud Landing using the MB data set.

For the Annapolis ROC curves shown in Figure 4.10, the ROC curve with a high AUC of 0.92
was generated using 10 variables. The AUC of 0. 92 indicates a predictive accuracy of 92% when

138

differentiating the Annapolis wine from the 14 other wines. The ROC curve was defined as a
mixture of NMR and DS assay features. The NMR bins covered a range of chemical shifts from
1.3 to 3.5 ppm, suggesting key metabolites defining Annapolis are potentially carbohydrates and
organic acids.

Figure 4.10: (A) The ROC curves for the Annapolis wine compared against the 14 other wine
samples. ROC curves were generated with MetaboAnalyst (https://www.metaboanalyst.ca/). The
graph shows the ROC curves generated using 5 (orange), 10 (blue), 15 (purple), 25 (teal), 50 (red),
and 500 (yellow) variables. (B) The top fifteen variables used to generate the ROC curves. The
frequency represents how often a variable is used in the ROC curve. MM1 to MM7 represents data
from the DS assay, while the numbers (ppm) are binned NMR data.

4.4.9.6 Sonoma Carneros
Sonoma Carneros is a wine region in California. Sonoma Carneros is one of the hottest wine
regions included in this study. The Huglin index is the highest at 2224.94. It also experiences the
highest growing low temperature at 9.88°C. Only one vineyard, Cloud Landing, was selected from
the Sonoma Carneros wine region.
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For the PCA models using the DS assay data, Cloud Landing clustered with Annapolis and
Bloomfield. Cloud Landing clustered with Boone Ridge and Nielson using the NMR data. Cloud
Landing clustered again with Annapolis and Bloomfield using the MB data set.
For the Cloud Landing ROC curves shown in Figure 4.11, the ROC curve with a high AUC of
0.936 was generated using 15 variables. The AUC of 0. 936 indicates a predictive accuracy of 94%
when differentiating the Cloud Landing wine from the 14 other wines. The ROC curve was defined
primarily by DS assay features, with MM2 560 as the top feature distinguishing the Cloud Landing
wine.

Figure 4.11: (A) The ROC curves for the Cloud Landing wine compared against the 14 other wine
samples. ROC curves were generated with MetaboAnalyst (https://www.metaboanalyst.ca/). The
graph shows the ROC curves generated using 5 (orange), 10 (blue), 15 (purple), 25 (teal), 50 (red),
and 500 (yellow) variables. (B) The top fifteen variables used to generate the ROC curves. The
frequency represents how often a variable is used in the ROC curve. MM1 to MM7 represents data
from the DS assay, while the numbers (ppm) are binned NMR data.
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4.4.9.7 Sonoma RRV
Sonoma RRV or the Russian River Valley is located in Sonoma County. It is also a rather hot wine
region with the highest high growing temperature of 25.77 oC. Sonoma RRV was the wine region
with the largest number of vineyards used in this study. Specifically, Sonoma RRV consisted of
vineyards: Carneos Hills West, Bloomfield, Bones, and Ross.

For the PCA models using the DS assay data, Carneos Hills West clustered with Bones, Gran
Moraine, and Maggy Hawk. Carneos Hills West clustered with Rice/Cambria, Radian and
Panorama 5A using the NMR data. Carneos Hills West clustered again with Bones, Gran Moraine,
Maggy Hawk/Falk using the MB data set. Carneos Hills West does not share a similar climate with
any of these vineyards.

For the Carneos Hills West ROC curves shown in Figure 4.12, the ROC curve with a high AUC
of 0.935 was generated using 25 variables. The AUC of 0. 935 indicates a predictive accuracy of
94% when differentiating the Carneos Hills West wine from the 14 other wines. The ROC curve
was defined by a majority of DS assay features. The NMR features included chemical shift bins
of 2.94, 2.91, 2.77, 2.21, and 1.36, which are likely organic acids.
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Figure 4.12: (A) The ROC curves for the Carneos Hills West wine compared against the 14 other
wine samples. ROC curves were generated with MetaboAnalyst (https://www.metaboanalyst.ca/).
The graph shows the ROC curves generated using 5 (orange), 10 (blue), 15 (purple), 25 (teal), 50
(red), and 500 (yellow) variables. (B) The top fifteen variables used to generate the ROC curves.
The frequency represents how often a variable is used in the ROC curve. MM1 to MM7 represents
data from the DS assay, while the numbers (ppm) are binned NMR data.

For the PCA models using the DS assay data, Ross clustered with MSA and Rice/Cambria. Ross
clustered with Annapolis, Bloomfield, Zena West, and Radian using the NMR data. Ross clustered
with Rice, MSA, and Radian using the MB data set.

For the Ross ROC curves shown in Figure 4.13, the ROC curve with a high AUC of 0.983 was
generated using 10 variables. The AUC of 0.983 indicates a predictive accuracy of 98% when
differentiating the Ross wine from the 14 other wines. The ROC curve was defined by a mixture
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NMR and DS assay features. The NMR features included chemical shift bins that ranged from
1.38 to 2.97 ppm, which are likely organic acids.

Figure 4.13: (A) The ROC curves for the Ross wine compared against the 14 other wine samples.
ROC curves were generated with MetaboAnalyst (https://www.metaboanalyst.ca/). The graph
shows the ROC curves generated using 5 (orange), 10 (blue), 15 (purple), 25 (teal), 50 (red), and
500 (yellow) variables. (B) The top fifteen variables used to generate the ROC curves. The
frequency represents how often a variable is used in the ROC curve. MM1 to MM7 represents data
from the DS assay, while the numbers (ppm) are binned NMR data.

For the PCA models using the DS assay data, Bones clustered with Carneos Hills West and Gran
Moraine. Bones clustered with Zena West and Maggy Hawk using the NMR data. Bones clustered
with Carneos Hills West and Gran Moraine using the MB data set.
For the Bones ROC curves shown in Figure 4.14, the ROC curve with a high AUC of 0.836 was
generated using 15 variables. The AUC of 0.836 indicates a predictive accuracy of 84% when
differentiating the Bones wine from the 14 other wines. The ROC curve was defined by a majority
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of DS assay features with MM9 444 and MM9 430 being the top features distinguishing the Bones
wine.

Figure 4.14: (A) The ROC curves for the Bones wine compared against the 14 other wine samples.
ROC curves were generated with MetaboAnalyst (https://www.metaboanalyst.ca/). The graph
shows the ROC curves generated using 5 (orange), 10 (blue), 15 (purple), 25 (teal), 50 (red), and
500 (yellow) variables. (B) The top fifteen variables used to generate the ROC curves. The
frequency represents how often a variable is used in the ROC curve. MM1 to MM7 represents data
from the DS assay, while the numbers (ppm) are binned NMR data.

For the PCA models using the DS assay data, Bloomfield clustered with Annapolis and Cloud
Landing. Bloomfield clustered with Ross and Annapolis using the NMR data.Bloomfield clustered
again with Annapolis and Cloud Landing using the MB data set.
For the Bloomfield ROC curves shown in Figure 4.15, the ROC curve with a high AUC of 0.98
was generated using 15 variables. The AUC of 0.986 indicates a predictive accuracy of 98% when
differentiating the Bloomfield wine from the 14 other wines. The ROC curve was defined by a
majority of DS assay features, but an NMR bin was top feature that differentiates Bloomfield from
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the other wines.
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Figure 4.15: (A) The ROC curves for the Bloomfield wine compared against the 14 other wine
samples. ROC curves were generated with MetaboAnalyst (https://www.metaboanalyst.ca/). The
graph shows the ROC curves generated using 5 (orange), 10 (blue), 15 (purple), 25 (teal), 50 (red),
and 500 (yellow) variables. (B) The top fifteen variables used to generate the ROC curves. The
frequency represents how often a variable is used in the ROC curve. MM1 to MM7 represents data
from the DS assay, while the numbers (ppm) are binned NMR data.

4.4.9.8 Anderson Valley
Anderson Valley is a wine region in Mendocino County California. Two vineyards, Boone Ridge
and Maggy Hawk, were selected from the Anderson Valley.

For the PCA models using the DS assay data, Boone Ridge clustered with Nielson and Panorama
5A. Boone Ridge clustered with Cloud Landing and Nielson using the NMR data. Boone Ridge
clustered with Nielson, Zena West and Panorama 5A using the MB data set.
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For the Boone Ridge ROC curves shown in Figure 4.16, the ROC curve with a high AUC of 0.809
was generated using 10 variables. The AUC of 0.809 indicates a predictive accuracy of 81% when
differentiating the Boone Ridge wine from the 14 other wines. The ROC curve was defined by a
mixture of NMR and DS assay features, where a number NMR bins were top features that
differentiates Boone Ridge from the other wines. The NMR bins corresponded to chemical shifts
that ranged from 1.49 to 4.06, which are likely carbohydrates and organic acids.

Figure 4.16: (A) The ROC curves for the Boone Ridge wine compared against the 14 other wine
samples. ROC curves were generated with MetaboAnalyst (https://www.metaboanalyst.ca/). The
graph shows the ROC curves generated using 5 (orange), 10 (blue), 15 (purple), 25 (teal), 50 (red),
and 500 (yellow) variables. (B) The top fifteen variables used to generate the ROC curves. The
frequency represents how often a variable is used in the ROC curve. MM1 to MM7 represents data
from the DS assay, while the numbers (ppm) are binned NMR data.

For the PCA models using the DS assay data, Maggy Hawk/Falk clustered with Gran Moraine,
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Carneos Hills, and Bones. Maggy Hawk/Falk clustered with Bones and Zena West using the NMR
data. Maggy Hawk/Falk clustered with Gran Moraine, Carnos Hills, and Bones using the MB data
set.
For the Maggy Hawk/Falk ROC curves shown in Figure 4.17, the ROC curve with a high AUC
of 0.929 was generated using 10 variables. The AUC of 0.929 indicates a predictive accuracy of
93% when differentiating the Maggy Hawk/Falk wine from the 14 other wines. The ROC curve
was defined nearly exclusively by DS assay features, with MM4 560 as the top distinguishing
feature.

Figure 4.17: (A) The ROC curves for the Maggy Hawk/Falk wine compared against the 14 other
wine samples. ROC curves were generated with MetaboAnalyst (https://www.metaboanalyst.ca/).
The graph shows the ROC curves generated using 5 (orange), 10 (blue), 15 (purple), 25 (teal), 50
(red), and 500 (yellow) variables. (B) The top fifteen variables used to generate the ROC curves.
The frequency represents how often a variable is used in the ROC curve. MM1 to MM7 represents
data from the DS assay, while the numbers (ppm) are binned NMR data.
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Anderson Valley vineyards did not cluster in the PCA models with vineyards that shared similar
climate conditions. Interestingly, ROC data curves were split in their utilization of NMR and DS
array data. Boone Ridge used a mixture of DS assay and NMR data favoring organic acids, while
Maggy Hawk used nearly all DS assay data.

4.4.9.9 Willamette Valley
Willamette Valley is located in Oregon. Willamette Valley is the least sunny and the coldest the
wine region used in this study. Its solar radiation is 131092.27 WH/m2 with the smallest Huglin
index of 1749. Willamette Valley also has the lowest high and low growing temperatures at 21.9
o

C and 8.1 oC, respectively. Two vineyards, Gran Moraine and Zena West, were selected from the

Willamette Valley wine region.

For the PCA models using the DS assay data, Gran Moraine clustered with Bones, Carneos Hills,
and Maggy Halk. Gran Moraine clustered with MSA using the NMR data. Gran Moraine again
clustered with Bones, Carneos Hills, and Maggy Halk using MB data set.

For the Gran Moraine ROC curves shown in Figure 4.18, the ROC curve with a high AUC of
0.976 was generated using 25 variables. The AUC of 0.976 indicates a predictive accuracy of 98%
when differentiating the Gran Moraine wine from the 14 other wines. The ROC curve was defined
by a majority of NMR features, with only three DS array values. The NMR bins corresponded to
chemical shifts that ranged from 1.99 to 4.27, which are likely carbohydrates and organic acids.
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Figure 4.18: (A) The ROC curves for the Gran Moraine wine compared against the 14 other wine
samples. ROC curves were generated with MetaboAnalyst (https://www.metaboanalyst.ca/). The
graph shows the ROC curves generated using 5 (orange), 10 (blue), 15 (purple), 25 (teal), 50 (red),
and 500 (yellow) variables. (B) The top fifteen variables used to generate the ROC curves. The
frequency represents how often a variable is used in the ROC curve. MM1 to MM7 represents data
from the DS assay, while the numbers (ppm) are binned NMR data.

For the PCA models using the DS assay data, Zena West clustered with Radian. Zena West
clustered with Nielson, Boone Ridge, and Panarama 5A using the NMR data. Zena West again
clustered with Nielson, Boone Ridge, and Panarama 5A using the MB data set.
For the Zena West ROC curves shown in Figure 4.18, the ROC curve with a high AUC of 0.95
was generated using 25 variables. The AUC of 0.95 indicates a predictive accuracy of 95% when
differentiating the Zena West wine from the 14 other wines. The ROC curve was defined with a
mixture of NMR and DS array features. The NMR bins corresponded to chemical shifts that ranged
from 0.86 to 3.50, which are likely carbohydrates and organic acids.
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Figure 4.19: (A) The ROC curves for the Zena West wine compared against the 14 other wine
samples. ROC curves were generated with MetaboAnalyst (https://www.metaboanalyst.ca/). The
graph shows the ROC curves generated using 5 (orange), 10 (blue), 15 (purple), 25 (teal), 50 (red),
and 500 (yellow) variables. (B) The top fifteen variables used to generate the ROC curves. The
frequency represents how often a variable is used in the ROC curve. MM1 to MM7 represents data
from the DS assay, while the numbers (ppm) are binned NMR data.
4.5 Conclusion
The goal of this project was to determine if a metabolomics profile can distinguish between
different PN wines based on vineyard, and to determine if wines with similar environmental
conditions have similar chemical profiles. Based on the PCA models and the ROC curve analysis
most PN wines was distinguishable with the either the 1D 1H NMR or the DS assay data. The PCA
models suggested that the NMR data provided a slight improvement over the DS assay data in
differentiating between the 15 PN wines, where Panorama 5A and Radian (p-value 0.05) and Zena
West and Bones (p-value 0.04) were the closest wine pairs. Surprisingly, a PCA model generated
by combining the NMR and DS array data sets resulted in poor group separation. Potentially, the
wine-dependent variance in the two datasets were partially anti-correlated. Also, a valid PCA
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model could not be generated when the individual wines were grouped according to wine region.
Suggesting a larger variance in the chemical profile of the individual wines that cannot be explain
by wine region alone. The fact that all 15 PN wines, despite originating from grapes from the same
clone (Dijon 667), were uniquely differentiated and could not be classified by wine region,
highlights that local environment and climate are key factors for determining the chemical profile
of a wine.

The ROC curves generated from the combined NMR and DS array data sets lead to variable
contributions of spectral features for the characterization of individual wines. Specifically,
depending on the wine, the ROC curves used different combinations of NMR and DS array spectral
features. In some cases, a ROC curve was nearly exclusively defined by NMR features, while other
wines were defined predominately by DS array data. There were also other cases where an equal
combination of NMR and DS array features were used to define a wine. Nevertheless, in all cases
the ROC curves yielded AUCs ranging from 0.80 to 0.98 indicating an accuracy of ≥ 80% in
characterizing the PN wines. In most cases, the ROC curves required only 5 to 10 spectral features.
Notably, a majority of the NMR spectral features used in the ROC curves corresponded to chemical
shifts in the 0 to 4 ppm region suggesting a potential importance of organic acids and carbohydrates
in differentiating the wines. Of course, the DS array data highlights the importance of phenolics to
classifying different wines. Our results are consistent with some prior studies in which differences
in isopentanol and isobutanol (0.9 ppm region) where observed to be key discriminators of La
Rioja wine terroir [29]. Similarly, changes in tannins and other phenolic compounds have been
attributed to changes in environmental conditions and grapevine vigor [30, 31].
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The second part of the study was to determine if wines harvested under similar climate conditions
or in the same wine region shared similar metabolomic profiles. Overall, our results demonstrated
that the PN wines were impacted significantly by local variations in environment and climate, and
likely other factors. In general, the PN wines could not be grouped by wine region or average
climate parameters using metabolomics profiles. Instead, each PN wine yielded a unique metabolic
profile. Pinot Noir wine are derived from vitis vinifera L. These grapes are associated with the
Burgundy region of France, but are grown around the world with the exclusion of hot climates.
Pinot Noir is known to take on the characteristics of the environment resulting in a distinct taste
[32], which is consistent with our overall findings. Goldman et al. examined different varieties of
red wine with 1D 1H NMR and found that PN had a 95% prediction rate, which is comparable to
our findings, but high compared to the other wines [33]. Thus, environmental and climate
conditions that vary between vineyard or are altered due to human action impact the metabolome
of wines.

Nicholas et al. evaluated climate variability on PN from the Carneros and Sonoma Valley in
California. Phenolic compounds and temperature were measured and correlated. Warm
temperatures from budburst to bloom were found to increase phenolic content; however, cooler
temperatures from the previous harvest negated this effect [31]. Reynolds et al. measured the effect
of water stress on PN fruit maturity and vegetative growth. Exposure to reduced water resulted in
a decrease in berry weight and an increase in soluble solids found in the grapes. Vegetative growth
was reduced with decreases in shoot length, number, and leaf size when exposed to reduced water.
This effect was also observed in grapes grown in soils that do not retain water [34]. Cortel and
Kennedy measured the effect of sunlight on PN grapes by comparing the flavonoid compounds
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found in shaded grapes compared to sunlight exposed grapes. Shaded grapes resulted in lower
levels of flavonoids, proanthocyanidins and anthocyanins [35]. Price et al. measured quercetin
glycosides at different levels of sun exposure and found an increase in grapes exposed to sunlight
[36]. Thus, numerous factors, including activities directly controlled by humans, impact how
grapes grow, and consequently, the chemical composition of the resulting wine. Overall, this study
exposed the complexities of terroir, its impact on metabolic profile of wine, and its utility to
accurately characterize PN wines derived from the same PN clone (Dijon 667).
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Chapter 5
5. Summary and Conclusion
5.1 Summary of Work
Metabolomics has seen applications in human diseases, plant genomics, and toxicology, among
numerous other research areas [1-3]. In fact, metabolomics is expanding into other areas of
investigation, such as the food industry. As a growing field, there is a strong need for standardized
methodologies for preparing metabolomics samples, conducting experiments, and analyzing
analytical data sets. As such, it is important to consider how samples are properly handled, and to
evaluate protocols for data processing, statistical modeling and the identification of metabolites.
Metabolites are unstable, and are often prone to oxidation or other forms of modification [4].
Therefore, the proper storage and transport of metabolomics samples is an important point to
consider. Metabolomics experiments generate large volumes of data, but commonly have limited
number of biological replicates. As a result, statistical and network analysis may be prone to
overfitting and over-interpretation. To address these and other issues, my thesis highlights the
development of metabolomics procedures and the application of metabolomics to issues related to
human health and food integrity.

Chapter 2 provides an exhaustive and detailed description of metabolomics protocols for the
investigation of Parkinson’s Disease (PD) and other neurological disorders. The described
protocols include methods to extract, quantify, and process metabolomic samples obtained from
mammalian cells and brain tissues [5]. Proper and complete metabolite extraction from a biological
sample is a critical step of the entire metabolomics protocol since it determines how much of the
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metabolome is available for study [6]. In this regard, Chapter 2 focuses on the extraction of watersoluble metabolites from cell lysis and the extracellular space or culture medium. Water soluble
metabolites include amino acids, sugars, and other organic acids. In addition to sample preparation,
Chapter 2 includes details regarding standard data collection for NMR and mass spectrometry, and
liquid chromatography. Typical statistical methods for the analysis of metabolomics data that
include principal component analysis and orthogonal projection to latent structures were also
described. Importantly, the described protocols include methods for validating multivariate
statistical models, such as permutation testing. Permutation testing validates supervised statistical
models by generating multiple replicate models using different subsets of the data while
scrambling group classification [7]. Furthermore, the importance of multiple hypothesis testing,
like Bonferroni and Benjamini-Hochberg, which help establish significance by controlling false
discovery rates, are also highlighted [8, 9].

Although the metabolomics procedures described in Chapter 2 can be applied to a variety of
metabolomic studies, the protocols were focused on investigating PD using neuroblastoma cells
and brain tissue. The complex heterogeneous nature of the brain makes metabolomics a useful tool
for providing an overview of cellular processes. Also, metabolomic studies are particularly useful
for neurological studies where regular access to tissues is difficult. Typical PD studies expose
animal models to various conditions to replicate PD symptoms or exposure risks. Similarly,
cellular models use neuroblastoma cells to reproduce PD changes and to mimic PD risk factors
[10]. Evidence suggests that the interactions between environment and genetics play an important
role in PD development [11]. Thus, animal or tissue models exposed to various environmental
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stressors are useful for investigating PD, other neurodegenerative diseases, or for monitoring brain
or neuronal health at different points in life.

Chapter 3 describes our investigation into astrocytes response to the neurotoxin arsenic.
Importantly, the outcome of this study may provide insights into how arsenic exposure may relate
to neurodevelopmental disorders in children. The role of astrocytes in the brain is a complex one.
Typically, astrocytes play a supportive role by providing neurotransmitter precursors to neurons
and by maintaining neuronal synapses [12]. However, astrocytes have been shown to respond to
immune or minor trauma in both supportive and harmful ways [13]. Astrocytes are known to be a
major source of glutathione, which protects the brain from oxidative stress and xenobiotics [14].
Astrocytes may also play a role in protecting neurons from bystander death (i.e., the death of cells
not directly impacted by an injury, toxin or radiation). Glial cells and neurons co-cultured with
astrocytes were protected from arsenic treatments [15].

In our metabolomics analysis of astrocytes exposed to arsenic, we observed an upregulation in
antioxidant production, which is possibly due to an upregulation of glycolysis and pyruvate
carboxylase. The production of glutathione (GSH) is dependent on glucose metabolism; therefore,
we focused our metabolomics analysis on the effect of arsenic on glucose metabolism. We
observed an increase in glutamate, a potentially neurotoxic neurotransmitter in the extracellular
space. Glutamate has been shown to upregulate glycolysis in astrocytes through activation of the
Na+ dependent uptake system [16]. We also observed a decrease in the export of lactate and citrate
by astrocytes. Lactate is a product of glycolysis and is derived from pyruvate; whereas, citrate is
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an intermediate of the tricarboxylic acid (TCA) cycle. Thus, lactate and citrate are known to be
energy substrates by entering the TCA cycle to produce ATP. However, recent evidence suggest
lactate and citrate may also play a role in modulating receptors like glutamate. Lactate has been
shown to modulate receptors linked to memory [17]. Similarly, citrate may modulate the glutamate
receptor MNDA by chelating Zn2+. Overall, our analysis of astrocytes exposed to arsenic
demonstrated a rapid metabolomics response to combat the oxidative damage induced by arsenic.

Metabolomics is valuable approach for evaluating the impact of a wide variety of environmental
stressors. Accordingly, metabolomics has been introduced into other areas of research, which
includes the food industry. The environment, handling and processing procedures may impact the
production of both food and beverages. Metabolomics can be used to produce a chemical profile
of a consumable, which allows food scientists to examine the impact of production, transport, and
storage on the food product. Wine is a prime example of a chemically complex food with
metabolites originating from plants, yeast fermentation, and sample aging [18]. Profiling is where
the chemical composition of the wine is measured. This is a useful tool for evaluating the nutrition
and health properties of a wine. For high value items like wine, chemical profiles are often used to
authenticate the wine’s origin for quality purposes. Chapter 4 examined Pinot Noir wines produced
from the same scion clone (Pinot noir 667) grown in vineyards across multiple California and
Oregon wine regions. Metabolite profiles were built from a combination of untargeted 1D 1H NMR
spectral data and a targeted differential sensing array data. The profiles were used to evaluate the
metabolic differences between the Pinot Noir wines produced by 15 vineyards. A major outcome
of the study was the observation that each method has its own advantages and limitations in regard
to classifying the wines. NMR captured a wide variety of molecules, such as carbohydrates and
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organic acids. Conversely, the DS assay was only used to detect phenolic compounds [19, 20]. The
1D 1H NMR and DS array data were evaluated individually and as a combined data set. A PCA
model produced from the NMR data set provided the best separation of the wines based on
vineyard of origin. Conversely, one versus all ROC curves were generated from the combined data
set. All of the ROC curves yielded a predictive accuracy of > 80% in distinguishing one wine from
the set of Pinot Noir wines. Notably, each resulting ROC curve used a different combination of
NMR and DS array spectral features to classify each wine. In some cases, the ROC curve was
dominated by either NMR or DS array features. In other cases, the ROC curve used an equal
mixture of both. Clearly, combining analytical techniques improved the overall wine classification
accuracy. Notably, the wines could not be consistently clustered by either wine region or by
average climate data. Thus, wine metabolic profiles are predominantly impacted by the local
environment (i.e., terrior), by the handling of the grapes/wine or by the fermentation process.

5.2 Future Direction
Metabolomics is a growing field and is constantly developing and refining techniques. As the
application of metabolomics continues to expand into new fields, it is important to consider how
the experimental design and the protocols will affect the desired results. As shown in chapter 4,
the application of different instrumentation or analytical methods will dictate the results or
outcomes of a given study. Simply, NMR and the DS array detected a completely different set of
metabolites and provided unique, but distinct views of each wine sample. In this regard, the
analytical method will determine which metabolites are detected. It will also determine how the
samples are prepared and how much sample is needed. Which, in turn, will impact the experimental
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time, the metabolome extraction protocol, and numerous other experimental parameters. These are
not trivial concerns. Following proper protocols reduces systemic error and exposes more of the
metabolome for proper characterization. Chapter 2 described the sample preparation protocol for
mammalian cells, but extraction and other procedures will vary based on the sample and the
analytical instrument. Thus, as the field of metabolomics continues to evolve, what is critical to its
future success is the establishment of a set of standardized protocols. Challengingly, these
protocols are likely to be sample and/or study specific.

NMR-based metabolomics often relies on the inclusion of a

13

C-labeled metabolite like

13

C6 -

glucose to enhance the sensitivity of the NMR experiment and the detection of metabolites [21].
Many biological and cellular reactions are independent of carbon movement and are therefore
difficult to monitor by only following central carbon metabolism. For example, many
phosphorylated compounds, which are involved in energy metabolism or regulate signaling
pathways, may be missed by relying on only 1H -13C-NMR [22]. Instead,
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P and other nuclei

NMR experiments will be needed to expand the coverage of the metabolome by NMR.

The application of metabolomics to clinical samples has further highlighted the important
differences between humans and animal models. Metabolomics may be valuable in breaching these
differences to facilitate drug discovery and disease diagnosis. For example, metabolomics may be
able to correlate disease relevant biomarkers across multiple platforms, from cell system, to animal
model, and then to the human patient. Identifying biomarkers for neurological disorders like PD
would allow for early diagnosis. An early diagnosis and intervention for PD has been shown to
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slow down the progression of symptoms. Leveraging metabolomics to identify risk factors for PD
may reduce exposure and prevent the disease. Metabolomics can make equally beneficial
contributions to the food industry. Metabolomics may be used to evaluate multiple aspects of the
food cycle - from growing food to its efficient processing. In this regard, metabolomics can be
used to improve anything from nutritional value to taste.
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